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H2-HPUra
ABSTRACT
6-(p-Hydroxyphenylhydrazino) uracil (H2-HPUra) is a selective and potent inhibitor of
the replication-specific DNA polymerase II (pol II) of Gram+ bacteria such as Bacilus
subtilis. Although a pyrdie, H2-HPUra derives its inhibitory activity from its specifc
capacity to mic the pure nucleotide, dGTP. The project described in this thesis
disserttion involves the use ofH2-HPUra-like inhibitors to probe the strctue and
function of the pol II active site. It consists of two separate problems which are
summarzed below.
CI H
-CH2
DCBG
Production of a potent bona fide. dGTP form of inhibitor. A method was devised to
successfully convert the H2-HPUra inhibitor prototype to a bona fide pure, using N2-
benzyl guanine as the basis. Strcture-activity relationships of benzyl guannes carng a
varety of substituents on the arl ring identified N2-(3,4-dichlorobenzyl) guanine (DCBG)
as a compound equivalent to H2-HPUra with respect to potency and inhibitor mechansm.
DCBdGTP, the 2' deoxyrbonucleoside 5' trphosphate form of DCBG, was synthesized
and characterized with respect to its action on wild-type and mutat forms of pol In.
DCBdGTP acted on pol II by the characteristic inhibitor mechanism and formally occupied
the dNP bindig site with a fit which permtted its polymerization. The latter experiment
identifed the site for the binding of the inhibitor s arl moiety as a distict site located at a
distace of approximately 6-7 A from the base-paied 2-NH group of a bound dGTP.
Attempt to covalently label amio acid residue 1175. a putative parcipant in inibitor
binding. Azp- , a point mutation of serie 1175, yields a form of pol In whose inhibitior
sensitivity vares specifically as a function of the composition of the para substituent of the
inhibitor s arl ring. On the basis of the latter behavior, residue 1175 was hypothesized to
be a residue diectly involved in the bindig of the inhibitor s arl moiety. To test this
hypothesis, residue 1175 was specifically mutated to either cysteine or lysine, each of
which presents a side chai amenable to covalent bond formation with appropriately
reactive inhibitor forms. Of the two mutat pol II forms, only the cysteine form (pol Ill-
cys) was catayticaly active. The kinetic propertes and inhibitor sensitivity profIe of pol
II-cys identified it as a taget suitable for potentially ireversible inhibitor forms containig
the following groups in the meta position of the arl ring: -CH2Br
, -
CH2Cl, and -CH2SH.
None of the several inhibitors tested selectively or ireversibly inactivated pol II-cys.
Possible bases for the faiure of this group of inhibitors and for the redesign of more useful
covalently reactive inhibitor forms are considered.
V11
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CHAPTER I
BACKGROUND
A. DNA-Dependent DNA Polymerases
Al DNA polymerases are primer-drven , template-dependent enzymes which catalyze
polymerization of the nucleoside 5' -monophosphate (dNMP) moiety of 2'
deoxyrbonucleoside 5' trphosphates (dNTPs) (Kornberg & Baker, 1992). They perform
ths function by catalyzing the extension of a 5' to 3' phosphodester- linked polynucleotide
along an antiparalel (3' to 5') template strand. DNA polymerases use Watson-Crck base
paing (Watson & Crick, 1953) furished by the hydrogen bondig substituents of the
bases to ensure correct dNP selection (Figure I- , page 2). With the exception of
retrovial reverse transcriptases (Alaudeen, 1980) and the mamalian DNA polymerase y
(Fry & Lob, 1986), both of which can use either a DNA or RNA template, DNA
polymerases generaly prefer to copy a polydeoxyrbonucleotide template (Kornberg &
Baker, 1992).
The salent features of the mechanism of DNA polymerase action are summarzed in
Figure I- , page 2. Incorporation of a dN moiety occurs by nucleophilic attack of the
OH group of the nucleotide at the prier termnus on the ex phosphate of the incoming
dN in the presence of Mg . The products of this reaction are a molecule of
TEMPLATE STRAND
fffffff1t
-f1111i1t1t
.. .. .. .. .. .. .. p. p. p. p. p. 
to 
. _.'_.-
-J,J pJQ1
---
SN \J \J \J \J \J \J 3' PPP OH I' PRIMER STRAND 5' 
Figue I-A: dN incorporation scheme. The template strd is that which furishes the
instrctions for the sequence of nudeotides to be added to the prier strd. The prier
strand is that which is grwing at the 3' OH termnus (Kornberg & Baker, 1992).
Reproduced with pennssion from Wright & Brown (1990).
pyrophosphate (PPi) and a template:prier whose prier moiety has been extended by one
dNMP residue.
DNA polymerases canot initiate a nucleotide chain de novo from a single dNTP. They
must be furished with the 3' OH of an NMP residue that has been linked, through its 5'
position, to an oligo or polynucleotide (ribo or deoxyrbo, Mak et al., 1985; Allaudeen
1980) or a protein (Blanco & Salas, 1986; Nagata et al., 1983).
B. Bacterial DNA Polymerases
The Gram+ bacterium Bacillus subtils, like the Gram- organsm, Escherichia coli
(Moses & Richardson, 1970; Kornberg & Gefter, 1971; Kornberg & Gefter, 1972;
Wickner et al. , 1972), has thee distinct DNA-dependent DNA polymerases. The three
enzymes are designated as polymerase (pol) I
, pol n and pol II (Okazak & Kornberg,
1964; Gass & Cozzarell, 1973a; Ganesan et al., 1973; Laipis & Ganesan, 1972; Gass &
Cozzarell, 1973b) and are encoded by the respective genes, polA, polB and polC. DNA
polymerase I, like the corresponding E. coli enzyme, is involved priary in the repai
synthesis of DNA (Okazak & Kornberg, 1964; Bazil & Gross, 1973). Pol II has no
known function in either E. coli (Masker et aI., 1973; Bonner et al., 1988) or B. subtils.
Pol III, the subject of this work, is an essential enzyme, specifcally required for the
replicative synthesis of the host chromosomal DNA (Cozzarell & Low, 1973; Nevile &
Brown, 1972; Brown, 1971).
C. B. subtils Pol Ill: Target of this Study and Model for Gram+ Pol Ills
The strctural gene for B. subtils pol III polC, has been cloned, sequenced, and
engineered for overexpression as a functional recombinant protein in E. coli (Bares &
Brown, 1983; Ott et al., 1986; Bares et al., 1989; Hamond et al., 1991; Hamond &
Brown, 1992; Bares et al., 1992). The pol III protein is a 162.4 kDa polypeptide
consisting of 1437 amo acids (Hammond et al., 1991). The protein possesses both
polymerase (pol) and 3' 5' edting exonuclease (exo) activity (Clements et al. , 1975; Low
et al., 1976). The site of exo catalysis, a region displaying considerable priar strctural
homology with the model developed for the 3' 5' exo site of E. coli DNA pol I (Bemad et
al. , 1989; Beese & Steitz, 1991; Derbyshire et al., 1991), has recently been localzed by the
Brown group (Bares et al., 1992) to a region withn the enzyme encompassed by amino
acids 420-510.
The integrated exo-pol strcture of B. subtils pol III is not miored in the strcture of
Gram- pol Ills, exemplifed by the enzymes of E. coli (Tomasiewicz & McHenr, 1987)
and the nearly identical Salmonella typhimurium pol II (Lancy et aI., 1989). Rather the
two catalytic functions are cared on two physically and genetically distinct subunits-a, a
130 kDa protein subunit caring the pol activity, and E, a 27.5 kDa subunit (Echols et aI.,
1983; Scheuerman & Echols, 1984) caring the exo activity.
Comparative amo acid sequence analysis has indicated signifcant homology (28%
identity) between amno acids 613- 1434 (Hamond et al., 1991) of B. subtils pol III and
the pol specific a subunits of the Gram
- pol Ils (Tomasiewicz & McHenr, 1987; Lancy
et al., 1989). Figure I- , pages 5-6, shows the sequence comparson made by Hammond
et al. (1991). The results of ths comparson and a wider comparson of the primar
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Figure I-B: Comparson ofthe deduced amino acid sequences of B. subtils pol III and the
(polymerase) subunit of E. coli pol Ill. Upper panel: Block diagr drawn to scale and
showing arangement and span of the regions of homology; solid lines, regions with no
signifcant homology; shaded boxes, regions of homology detaied in lower panel; open
box (exo), block of homology with the DNA E exonuclease (detail not shown; Sanjanwala
& Ganesan, 1989; Ito & Braithwaite, 1991; Bares et al., 1992). Lower panel:
Comparson of shaded blocks shown in upper panel. Last digits of numbers are aligned
with correspondig amo acid (aa); colon, identical aa residues; single dot, either aa
equivalence or codons difering in one base; dash, presence of gaps. Reprited with
permssion by Hammond et al. (1991).
strctures of bacterial pol Ils with those of ::20 other DNA-dependent DNA polymerases
strngly suggests that the pol Ils constitute a strctualy unique famy (Famly C; Ito &
Braithwaite, 1991) of enzymes, distinct from enzymes of eukarotic and viral origin.
It is liely that many bacteral pol Ils wil be added to this family as their sequences are
elucidated (Ito & Braithwaite, 1991).
D. H2-HPUra-Type Inhibitors
Pol Ills of B. subtilis and other Gram+ bacteria display a property not observed for the
correspondig replication-specifc enzymes of Gram- organsms: they are uniquely
sensitive, both in vivo (Brown, 1970) and in vitro (Bazil & Gross, 1972; Brown et aI.,
1972; Nevile & Brown, 1972; Cozzarell , 1977), to the inhibitory effects of 6-
(arlhydrazino) pyrmidies, a novel class of antibacterial agents whose prototype is 6-(p-
hydroxyphenylhydrazino )uracil (H2- HPUra).
The inhibitor famly prototype, the "prodrg" azo form, 6-(p-hydroxyphenylazo)uracil
(HUra), was originaly synthesized by Bernard Langley of Imperial Chemical Industres,
Ltd. where it was observed to be a potent inhibitor of the growth of Gra+ bacteria and to
be without signifcant effect on the growth of Gram- bacteria or anima cells. Its selective
toxicity for Gram+ organsms prompted Brown and Handschumacher to explore its
mechanism in the Gra+ bacterium Streptococcusfaecalis, using HPUra (Figure I-
page 8) as the model inhibitor. The results of their studies (Brown & Hadschumacher
1966) indicated that HPUra inhibited the replicative synthesis of DNA and, furer, that it
achieved this effect selectively, without inhibiting RNA , protein or cell wal synthesis, or
the pathways involved in dNTP synthesis. Brown then extended this work to Bacilus
HN 
N=N 
( )
Prodg (inactive form)
(H) (Reduction)
HN 
N-NH H
Active Form
Figure I-C: Top: Strcture of HPUra, the oxidized inactive form of the drg. Bottom:
Strcture of H2- HPUra, the reduced form of the drg, which is active on the isolated
enzyme. Reduction (H) in vivo, in the bacterial cell, occurs by an unkown mechanism.
Reduction in vitro is readily accomplished with reducing agents such as sodium dithionite
(Neville & Brown, 1972) or dithiothreitol (DIT) (Gass et al., 1973).
subtils where he determed that DNA repai synthesis, unlike replicative synthesis, was
completely resistant to HPUra (Brown, 1970; Brown, 1971).
Subsequent work with toluene-trated permeable B. subtils revealed two importt
facts about drg action (Brown, 1972; Brown et ai. 1972). First, it revealed that the azo
form, HPUra, is inactive on its taget and requires reduction to the hydrazino form (H2-
HPUra, Figue I-C, page 8) to effect enzyme inhibition, and second, it indicated that this
active hydrazino for acts by mimicking the purie dNP, dGTP (Brown, 1972). The
action ofH2-HPUra is specifically and competitively reversed by dGTP. The specific
target of H2-HPUra was elucidated by in vitro analysis of its action on the thee isolated 
subtils DNA polymerases (Neville & Brown, 1972; Gass et al., 1973; Mackenzie et al.,
1973). H2-HPUra inhibited only pol il, and was without significant effect on either pol I
or pol II.
dro en bondin with te late c tosine. The abilty to mimic dGTP suggested that
the inhibitory action ofH2-HPUra resided, in par, in its abilty to base pai, lie guanine,
with an unapposed template cytosine. The results of three sets of experients confirmed
ths suggestion. The fIrst experiment examned the effects of H2-HPUra on the activity of
pol II in the presence of the synthetic template:priers, poly(dC):oligo(dG) and
poly(dA):oligo(dT). H2-HPUra inhibited the poly(dC):oligo(dG)-mediated reaction and
had no inhibitory effect on poly(dA):oligo(dT)-mediated synthesis (Clements et aI., 1975).
The second set of experiments analyze interactions between H2-HPUra and cytosine via
proton NMR. The results showed specifc downfield changes in chemical shifts for the
hydrazino N-6 and NH- l proton signals of H2-HPUra in cytosine-contaning solutions
(Mackenzie et al. , 1973). The thd set consisted of studies of the crystal strcture of H2-
J;.
HPUra itself. The results cOIToborated those established by NMR and confirmed the base
paig scheme shown in Figure I- , page 11, (Coulter & Cozzarell; 1974, Coulter &
Cozzarell, 1975), a scheme which clearly ilustrated the pure-like behavior ofH2-HPUra
and its specific capacity to mimic dGTP.
Seqestrtion Durng the coure of investigation of drg mechanism, it became clear
that H2-HPUra action did not depend solely on the capacity of this drg to compete with
dGTP for the hydrogen bonding sites on template cytosine (Wright & Brown, 1990). The
best evidence of a more complicated mechansm came from the observation that H2-
HPUra, in the presence of natual cytosine-containing template:primer DNA, strongly
inhibited the residual synthesis catalyzed by pol III under "trncated" (-dGTP) conditions
(Wright & Brown, 1976). The abilty ofH2-HPUra to inhibit the dGTP-independent
catalytic activity of pol II clealy suggested that the inhibitor, in the presence of a cytosine-
contang template, induced the seuestration of pol il in an inactive DNA-enzyme-drg
complex.
The fIrst clear evidence for complex formation was obtained in an experiment which
used poly(dA):oligo(dT) as the pricipal template:primer. As indicated above, this DNA
cannot base pai with H2-HPUra and thus, dA:dT drven synthesis is resistant 
inhibition. However, the addition of a small amount of activated (cytosine-containing)
DNA, which alone produced an insignificant amount of dTM incorporation, caused the
mai poly(dA):oligo(dT)-drven reaction to become drg sensitive (Gass et al., 1973).
These results indicated that H2-HPUra sequestered enzyme on the cytosine-containing
template:prier, leavig little enzyme available for incorporation of dTM by the
homopolymer template:prier.
H -1; 
H-N
\INMP
dCMP
dNMP
1 JN
1; 
H-N
dNMP
dGMP
dCMP
Figue I-D: Proposed mechansm of H2-HPUra:cytosine base paig. The pars of the
molecules which parcipate in base paig are the 4, 3 and 2 moieties of cytosine and the
, 1 and 6-NH positions ofH2-HPUra (left), which behave lie the 6, 1 and 2 moieties of
guanine (right). dN symbolizes the 2' deoxyrbosyl 5'-monophosphate moiety of each
nucleotide.
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The above results were cOIToborated by the results of a series of experiments that
examned the effects ofH2-HPUra on the elution behavior of pol Ill, DNA and pol llI-
DNA mitures on an agarose gel column (Clements et al., 1975). In the absence of drug,
both DNA and pol III eluted separately on this colum, and H2-HPUra did not affect the
elution profies of DNA or enzyme alone. In the presence of drg, however, enzyme and
DNA that had been loaded together were coeluted from the column (Clements et al., 1975)
indicating that they had become complexed. Thee ancilar observations supported these
results. First, the inactive, azo form of drg, HPUra, did not promote complex formation.
Second, the Ki concentration ofH2-HPUra and Kcx, the concentration ofH2-HPUra
requied to induce hal-maim DNA-enzyme complex formation, were essentially the
same (Clements et al., 1975). Third, dGTP, which specifically and competitively reversed
drg-induced inhibition of pol llI, also specificaly antagonized complex formation
(Clements et al., 1975).
E. H2-HPUra: Model for its Proposed Mechanism of Action
Workig independently, Low et al. (1974) and Clements et al. (1975) proposed
identical molecular models to explain the observed actions of H2-HPUra on pol m. The
proposed model, taken from a schematic diagram of Brown and Wright (1977b), is shown
in Figue I-E, page 13. The complex is ternar, composed of polymerase, template:primer
DNA and a base-paied drg in a 1:1:1 stoichiometr. H2-HPUra behaves as a bridge,
linkg pol II and DNA by hydrogen bonding with a template cytosine immediately dista
to the 3' OH primer termus and interacting, via its arl moiety, with an enzyme site close
PRIMER STRANO TEMPLATE STRANO
Figure I-E: Proposed model of H2-HPUra mechanism. Drg sequesters DNA and enzyme
into a reversible ternar complex. Ths figure is copied with permssion from Brown &
Wright (1977b).
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to, if not identical with, its dNTP binding site (Brown & Wright, 1977b). The interactions
of DNA and enzyme have been assumed, in the model, to be the same as those which
govern normal (drg-free) prier extension and which position the 3' OH termnus of the
DNA such that polymerization of the inhibitor could occur if it were in a bona fide dNP
form (see Figure I- , page 13).
F. Strctual Requiements for the Inhibitory Action ofH2-HPUra and its Derivatives
H2-HPUra, as shown by NMR and crystal studies, must be able to hydrogen bond with
template cytosine with its 6, 1 and 2 pyrmidie ring moieties (see Figure I-D, page 10). A
varety of strctual analogs ofH2-HPUra affecting these substituents was synthesized in
order to determe strctue-activity relationships (Wright & Brown, 1974; Wright &
Brown, 1976). Many substitutions can be made on the H2-HPUra strcture without
altering the guanine-like charcter of the inhibitor (Wright & Brown, 1977). Substitutions
which change the abilty of the inhibitor to base pair with cytosine include replacement of
the oxo group at carbon 2 of the pyrdine ring with an amino group. This rearangement
gives an equaly potent inhibitor but changes its character to that of a dA TP-specific analog
(Wright & Brown, 1976; Mackenzie et al., 1973) which requires dATP to effect reversal of
inhibition (Wright & Brown, 1976).
When the 6-NH moiety is allated or replaced with a methylene group, inhibitory
activity is abolished. This is not the case for the NH moiety proximal to the arl ring. This
NH can be replaced with a methylene group or entirely removed. Appropriately substituted
benzylamo and anlino urcils are just as potent as their corresponding phenylhydrazino
uracils (Brown et al., 1977).
Another strctural requirement of the H2- HPUra inhibitor format is the presence of a
planar, unsaturated arl group. Removal of the arl moiety and replacement with alkyl
substituents or satuate cyclic substituents results in a loss of inhibitory activity (Wright &
Brown, 1980; Brown et al., 1986). A varety of arl rig substituents are compatible with
matenance of inhbitor potency. For example, most small meta or para alkyl or halo
groups (which are hydrophobic in natue) maintain potency at the 0. 2j.M Ki range
(Wright & Brown, 1977). Second, ortho substituents of any size or chemical nature are
not tolerated and result in a major loss of potency (Wright & Brown, 1977), a loss likely
due to steric hindrce of the mobilty of the arl moiety relative to the heterocyclic ring.
Inhibitors with electron-withdrawing groups (i.e., N02 and C02H) also show remarkably
decreased activity, likely resulting from electronic effects (Wright & Brown, 1977).
Wright and Brown sought to develop HPUra-like 6-substituted uracils that would not
require a chemical reduction to maitai inhibitory activity, and to purue this goal, they
synthesized a series of uracils which are sumarzed in Figure I-F, page 16. The
azo/hydrazio form of uracil was altered to produce a series of 6-anlinouracils (IA) and 6-
benzylamnouracils (lB) (Brown et al., 1977; Wright & Brown, 1980). Several 6-
anlinourcils proved to be potent inhibitors, paricularly those with larger hydrophobic
groups such as 6-(3,4-trmethyleneanilino)uracil (TMU). In general, benzylamino uracils
with substituents equivalent to those of the phenylhydrazino uracils (Wright & Brown,
1977) had simar KiS, indicating that the positioning of the arl moieties of the two
inhibitor typs was similar.
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Figure I-F: The evolution of H2-HPUra-like inhibitors. Brackets indicate the base pairing
domains of each prototye.
Following the development of the anilino and benzylamo derivatives, Wright and
Brown sought to constrct 2' deoxyrbonucleotidyl forms of the inhibitors. This constrct
was not possible with the uracil nucleus because pyrmidine glycosylation , which occurs at
Nl of the heterocycle, would destroy the capacity of the pyrmidine to base pair with
cytosine. Therefore, Wright and Brown used an alternative approach to nucleotide
constrction and developed a route based on the use of N2_substituted guanine (N2 G) as
the heterocyclic nucleus. Because glycosylation of pures such as N2 G occurs at the 9
position, the N2 G nucleus provided a strctual basis for nucleotide synthesis without
compromising the integrty of the essential base paing domain. Two specific classes of
N2-substituted guanines, N2-arlguanines (2A) and N2-benzylguanines (2B), were
synthesize. The most potent phenylguanine, N2-(3,4-trmethylenephenyl)guanine
(TMP), the guanne form cOlTesponding to 6-(3,4-trmethyleneanilno)uracil (TMAU),
was nearly as potent as TMU on the isolated pol III in vitro, but was unable to penetrate
intact cells (Wright et al., 1982).
G. Pol II Azp- 12: a Drug- Resistat Mutant Enzyme
PolC az- 12 (Clements et al., 1975) and PolC22 (Cozzarell & Low, 1973) are mutant
pol II strctural genes which were identified on the basis of the HPUra-resistant growth
phenotye they confer upon their hosts. It has recently been determned, through
sequencing, that these mutat polymerases result from the same amino acid change - serine
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1175 to alanine (S1175A; Sanjanwala & Ganesan, 1989; Bares et al., 1989; Bares et aI.,
1992). S 1175A has been useful to the study of polC and its enzyme product, pol III, in
several ways. Firt, it established the central role of pol III in replication of B. subtils
chromosomal DNA (Clements et al., 1975; Cozzarell & Low, 1973). Second, it became
the means though which the Brown lab cloned polC and mapped its location on the 
subtils chromosome (Lve et al., 1976; Bares & Brown , 1983; Ott et aI., 1986). Third,
the assessment of the mutant s catalytc properties has provided important information
regarding the strctue of the inhibitor binding site.
Pol III azp- 12 is specificaly resistant to H2-HPUra and other analogs caring OH or
other polar substituents in the para position (Brown & Wright, 1977a). Although resistant
to this dGTP analog, the mutat enzyme maintais the same Km for dGTP and other dNTP
substrates, and it displays a near identical Vmax for polymerization (Clements et aI., 1975).
The latter observations have suggested that the dN and inhibitor binding sites are not
formally identical.
The strctue-activity relationships indicated above in section F suggest several features
of the arl binding site. First, the bindig site is hydrophobic and comprised of
components which are liely aranged in a coplanar configuration , giving the site the abilty
to interact strongly with the phenyl ring of the inhibitors through van der Waals
interactions. Second, the S1175A mutation (pol III azp- 12) reduces only the interaction of
hydrophilc arl substituents such as that on H2-HPUra, suggesting that a secondar,
weaker hydrophiic site of interaction exists that is not in diect contact with the phenyl
ring. It is postulated that the -CH20H moiety of serie 1175 provides this interaction and
therefore, when it is changed to alanne (azp- 12), the resultant methyl side chain may cause
repulsion of the polar -OH substituent of H2-HPUra, weakening its binding and potency as
an inhibitor.
CHAPTER 
STATEMENT OF THE THESIS PROBLEM
My thesis research project focuses on B. subtilis pol lll. It is derived from the long
range objective of the Brown laboratory to elucidate, in molecular detail, the strcture and
function of the dN bindig domain of the polymerase active site and to determne the
essential features of this doma that make Gra+ pol Ils uniquely reactive with the H2-
HPUra inhibitor prototype.
My project has posed and addressed two major questions: (1) Physically, how are the
arl and dN bindig sites of pol II related? Do they overlap or are they formally
distict? (2) Does there exist, among a collection of several untested inhibitor forms, any
which is a strong candidate for use as a covalently reactive marker of the 
arl binding site?
How questions 1 and 2 were addressed experimentally and how each question was
answered are presented, respectively, in Chapters III and IV.
CHAPTER III
ARE THE ARYL AND dNTP BINDING SITES OF POL III
FORMALLY SEPARATE OR DO THEY OVERLAP?
A. Approach
To address this question experimentaly, I proposed to synthesize and exploit an
inhibitor form in which a pol II-specific arl moiety was incorporated into the N2 position
of dGTP, the 2' deoxyrbonucleoside 5' trphosphate with which the simple base forms of
the H2-HPUra prototype are specificaly competitive. This approach was analogous to that
taen with the mamalan DNA polymerase a-specifc inhibitor N2-(p-n-
but ylphenyl) guanine (BuPG) (Kan et aI., 1984). The conversion of BuPG to its
corresponding 2' deoxyrbonucleoside 5' trphosphate form increased its potency
approximately l00-fold, from a Ki of 12 J.M to less than 10 nM (Khan et aI., 1984).
Specifically, I sought to determne for the pol II case: (a) if such a dNTP form would
retain the characteristic, H2-HPUra-lie mechansm of action, and (b) ifthe dNMP moiety
of this dN form is polymerized to the 3' OH group of the primer terminus while resident
in the terar enzyme: DNA: inhibitor complex. If the results of the determination of
questions (a) and (b) were negative, no definitive information about site overlap would
likely be gained. However, if the determnation of questions (a) and (b) yielded positive
results, it could be fiy concluded that the dNP and arl moieties bind simultaneously to
very closely neighboring, but formally separate, sites.
The fIrst step was to screen existing compounds from the benzylguanine family to select
one or more that were more potent or equaly potent with the corresponding uracil
dervative.
B. Results and Discussion
Screenine- fo pote t pol III inhi
Table ill- , pages 23- , displays the results from the search for a potent bona fide
guanine inhibitor. In nearly all cases, the phenylhydrazinouracils such as H2-HPUra and
the benzylamouracils such as OH BAU were more potent than their corresponding
guanines. This held tre for compounds substituted with both hydrophilc and
hydrophobic groups. However, N2_(3, dichlorobenzyl)guanine (DCBG) proved to be as
potent as DCPUra and DCBAU on both wild type and azp- 12 pol Ins. While azp-
maintaned resistance to those inhibitors with hydrophilc substituents such as H2-HPUra
and equal sensitivity to unsubstituted inhibitors such as H2-PUra, it became more sensitive
to inhibitors with hydrophobic substituents such as methyl groups. DCBG fell into the
latter category in that it was more potent on the azp- 12 enzyme.
, j
Table il-
KiS (f,M)
x Substituent wt pol III azp12 pol ill
Serine 1175 Alanine 1175
X= Hydrophilc
OH (H2-HPUra) (a) 0.4
OH (p-OHBAU) (b) 1.0
OH (P-OHBG) (b) 700
NH2 (p-NH2Ura) (a)
NH2 (P-NH2BAU) (c) 156
X=H
H (H2-PUra) (a) 1.4
H (BAU) (c) 2.3
H (BG) (d) 300 500
X= Hydrophobic
CH3 (H2- TolUra) (a) 1.0 0.4
CH3 (p-MeBAU) (e)
CH,: (p-MeBG) (e)
X= 3,4-diCI
diCI (DCPUra) (a)
diCI (DCBAU) (e) 075
diCI (DCBG) (e)
STRUCTURES
PUra BAU
N=N-OX
BG 
I(CH2'
Table llI-A: Strctue activity relationships of uracil and guanine analogs ofH2-HPUra.
KiS were determned by the trncated assay described in Chapter VI. The structural
backbones of each inhibitor tye are drawn above. (a) Synthesis was described by Wright
and Brown, 1977. (b) Synthesized by Dr. L. Dudycz. (c) Synthesis was described by
Brown et aI., 1977. (d) Synthesis was described by Hildebrand et aI., 1990. (e) Synthesis
was described in Chapter VI of this thesis.
qpertes of N2 (3.4 dic orobe yl)guanine. ( the model enz uanine
oited for cOI:po ation into a dGTP at.
(i Action of DCBG on the isolated polymerase is characteristic of the H2-HPUra
prototype. My strategy for development of the nucleotide form of the inhibitor required
that the simple N2-substituted guanine base on which it was to be constrcted: (a) be
potent (i.e., display a Ki in the 0. M range), (b) be specifically competitive with dGTP
lie the corrspondig 6-(benzylamino) and 6-(arlhydrazino)uracils, and (c) be dependent
on the presence of a cytosine-containing template. DCBG, one of many candidates
avaiable from Dr. George Wright, met all three requirements. First, DCBG was a
characteristically potent inhibitor of wild-type pol llI, displaying a Kj of approximately 0.
Jl (see Table llI-C, page 30). Second, its inhibition was specifically and competitively
reversed by dGTP (Figure III-A, page 26); high concentrations of dATP, dCTP , or dTTP
had no effect on its inhibitory capacity. Third, when the action of DCBG on pol III was
assessed with either poly(dA):oligo(dT) or poly(dC):oligo(dG) as template:primer, it, like
H2-HPUra (Gass et al., 1973; Clements et aI., 1975), inhibited only the latter reaction
(Table III- , page 27).
(ii) Action on intact cells: specifcity for replicative DNA synthesis. DCBG, like
HPUra, which is reductively activated in vivo, penetrated intact B. subtils and inhibited its
capacity to form colonies on meda plates. Microscopic examination of B. subtils grown
in liquid medum for a period of time equal to four generations of growth , in the presence
of 100 M DCBG showed that the drg arested cell division and effected a segmented
morphology typical ofHPUra-treated cells which are specifically unable to synthesize DNA
No Drg
50 DCBG
150 DCBG
1 0.
If( dG TP) (JM-
0.4
Figure llI-A: Competitive inhibition of pol III by DCBG. Polymerase assays were
perormed as descrbe in Chapter VI with varing concentrations of dGTP and the
indicated concentrations of inhibitor, DCBG.
dNMP incorporation (pmoles) (a)
System +DCBG +H2-
Control (80 JlM) HPUra
(80 11M)
(a- 32PJdGTP poly( dC) :oligo( dG )(b) 12.
(3HJ dTT poly(dA):oligo(dT)(b) 12. 12. 12.
Table llI-B: Template dependence of inhibitor action. (a) based on an assay mix containing
a speifc activity of 825 cpm/pmole. (b) Polymer:oligomer assay conditions are described
in Chapter VI, Section F.
(Brown, 1970). Figure Ill- , page 29, summarzes the effect of DCBG on macromolecule
synthesis in log-phase B. subtils, based on analysis of incorporation of labeled adenine
into RNA and DNA, and labeled leucine into protein. The results clearly indicated that
DCBG, like HPUra (Brown & Handschumacher, 1966; Brown , 1970), inhibited only
DNA synthesis and displayed no significant effect on the synthesis of RNA and protein.
(iii) Utility ofDCBG as an agentfor selecting and identifying bacterial clones carrying
mutations affecting the drug binding site of pol III. Much of the value of the H2-HPUra
inhibitor prototype as a genetic and strctural probe of the replication-specific DNA pol III
is derived from its "magic bullet" capacity to select, on drg-containing nutrient plates,
bacterial clones which car mutationally altered, drg-resistant forms of pol III. 
subtilis az- , a mutat displaying both an HPUra-resistant growth phenotype and an H2-
HPUra-resistat pol III (Clements et aI., 1975) exemplifies this strong correspondence of
in vitro enzyme "phenotype" and the growth-response phenotype of its host. As shown in
Table Ill-C, page 30, comparson of the action of DCBG and H2-HPUra on the wild-type
and az-12-specifc systems indicated that DCBG also could consistently discriminate
between wild-type and mutant forms of pol llI, both in vivo and in vitro. The top row of
data, displaying KiS for in vitro enzyme inhibition, indicated that the azp- 12 enzyme,
relative to wild-tye enzyme, showed approximately 55-fold resistance to H2-HPUra and,
interestingly, 5-fold hi ivi to DCBG. The second row of data displayed the
same trend in vivo; the growth of the azp- 12 mutant host, relative to that of the wild-type
host, was approximately 8 ties more resistant to HPUra and 8 times more sensitive to
DCBG.
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Figure II-B: RNA, protein and DNA synthesis in the presence of DCBG or HPUra.
Cultures of B. subtilis NB841 were grown and incorporation of (3H)-adenine into RNA
and DNA and (3H)-leucine into protein were followed as described in Chapter VI.
Inhibitors or control diluent were added at tie zero.
wil ype syst 12 s stem
H2-HPUra DCBG H2-HPUra DCBG
Isolated pol II
(Ki (J,)(a)) 0.4 + . 5 +. 22+4 1 +.
Bacterial division
CFSO (llM)(b,
Table TII-C: In vitro vs in vivo effects of DCBG and H2-HPUra. (a) Ki was determined as
descrbed in Chapter VI. (b) CFSO is the concentration of inhibitor in minimal salts agar
plates requied to reduce the number of colony-forming units of B. subtils (strain BD54;
Vrooman et al. , 1978) to 50% of control values. (c) HPUra, in its oxidized native form
was used in the determation of bacterial growth.
s of Nb(3.4 dic oroben deo ygua sine hos hate CBdGTP
Given the favorable assessment of DCBG as an H2-HPUra-like inhibitor, I synthesized
and charcterzed its dNTP form, DCBdGTP. The synthetic pathway used to obtain
DCBdGTP is ilustrated in Figure ITI-C, page 32, and described in detail in Chapter VI
Section C. Step A was performed as described by Wright and Dudycz (1984). Step B
involved chlorination of thebenzylguanine with POCl3 to produce the 6-chloro base.
Glycosylation (Step C) involved reaction of the 6-chloro purine with a protected 2'
deoxyrbofuranosyl chloride in the presence of sodium hydrde (Wright et al" 1987). The
resulting 9- 6-chloro nucleoside was hydrolyzed to the deoxyguanosine derivative by
reaction with 2-mercaptoethanol and sodum methoxide (Step D). Phosphorylation of the
nucleoside with POCl3 (Step E) gave the nucleoside 5'-monophosphate (Yoshikawa et ai.,
1967). In Step F, the monophosphate was pyrophosphorylated to generate the
trphosphate, DCBdGTP (Ott et al., 1967; Blackburn et aI., 1981). The IH and 31p NMR
spectra served to identiy each of the above compounds (see Chapter VI , Section C).
Propertes of TP actio its pol III tar et. The properties we sought in the
dN form were: (a) a potency at least equivalent to that of the simple base fonn, DCBG;
and (b) a mechanism equivalent to that of the base. The results of experiments described
in subsections (i)-(v) below summarze the assessment of these properties.
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Figue Ill-C: Summ of the synthetic pathway from 2-bromohypoxanthine to the final
product, DCBdGTP. Detals are presented in Section C of Chapter VI.
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(i) Potency and discrimination of wild-type and mutant pol Ills. As Table III-D, page
34, indicates, the dN inhibitor form, DCBdGTP, was 4-5 fold more potent than DCBG
for both wild-tye and azp-12-specific enzymes. The presence of the dNTP moiety did not
change the abilty of the DCBG nucleus to discrnate the wild-type and azp- 12 enzymes
in vitro. The ratio of the Ki for az-12 to the Ki for wild-type was the same for both
DCBG and DCBdGTP (ie. 4-5 fold, Table Ill- , page 34).
(ii) Specifc reversal by dGTP. Like the parent compound, DCBG, the trphosphate
form, DCBdGTP was specifically reversed by dGTP. High concentrations of dA TP,
dCT, and dTT under identical assay conditions had no effect on its potency (Table III-
page 35).
(iii) The template cytosine requirementfor DCBdGTP- induced inhibition is preferred
but not absolute. Competition experients, identical to those performed with DCBG,
indicated that the inhbitory action of DCBdGTP, in the presence of activated natural (calf
thymus) DNA, was competitively and specificaly antagonized by dGTP as shown in
Figure Ill-D, page 36. Given this observation, I exploited the homopolymeric
template:primers, poly(dA):oligo(dT) and poly(dC):oligo(dG) to determne whether the
action of the dNTP form, like that of the parent base, DCBG, absolutely required template
cytosine to effect inhibition. The results of the homopolymer experiments are summarzed
in Table III- , page 37. DCBG, like H2-HPUra (Gass et al., 1973; Clements et aI.
1975), displayed no signicant inhibition in the absence of template cytosine. In contrast,
DCBdGTP, although considerably more potent in the poly(dC)-drven reaction (ICSO = 7
M), displayed significant activity (ICso = 200 M) in the poly(dA)-directed reaction. The
Ki (l1M)
Compound
wt pol III azp12 pol il
DCBG
DCBdGTP 025
Table III-D: Potencies of the base and nucleotide forms of DCBG. KiS were detennined
as described in Chapter VI. The standard deviation for all Ki values was no greater than
+/- 20%.
Conditions
Control (b) -DCBdGTP
Control + 0.5 M DCBdGTP 1.1
500 MdATP + 0. M DCBdGTP 1.2
500 M dCTP + 0. M DCBdGTP 1.1
500 M dTTP + 0. DCBdGTP 1.2
500 dGTP + 0. M DCBdGTP
Table III-E: Effects of high concentrations of dNTPs on inhibition of pol III by
DCBdGTP. (a) Incorpration of the appropriately labeled dNTP was monitored as
descrbe in Chapter VI, Section F, using activated calf thymus (C.T. ) DNA. The labeled
dN was (a-32p) dATP for the experients assessing the effect of high dCTP , dTTP and
dGTP concentrtions and was (3H) dTTP for the experient assessing the effect of high
dATP concentration. The specific activity of each labeled dNTP was 625 cpm/pmole. (b)
Control conditions consisted of the standard trncated (-dGTP) assay.
No Drg
M DCBdGTP
25 f. DCBdGTP
100 M DCdGTP
l/(dGTP) (J.-
Figure TII-D: Competitive inhibition of pol il by DCBdGTP. Polymerase assays were
performed as descrbed in Chapter VI , Section F.
dNMP incorporation (pmoles)UU
DNA System Control +DCBG +DCBdGTP
(100 IlM) (100 jlM)
(a-32p) dGTP 12. 1.0
polv(dC):oligo(dG)
(3H) dTT 13. 13.
poly ( dA):oligo( dT)
Table II-F: Template dependence of inhibitor action. Polymer:oligomer assays were
performed as descrbed in Chapter VI in the presence of 20 jlM (a-32p) dGTP or (3H)
dTTP at a specific activity of 825 cpm/pmole.
basis for the template "independent" activity of DCBdGTP, although not clearly
established, is likely relate to its explicit and complete dNTP strcture, which enhances its
capacity to recognize and diectly bind the enzyme s dNTP binding site. I tested this
possibilty by examning the effect of increasing the concentration of dTTP in the
poly(dA):oligo(dT)-drven reaction on the sensitivity of the reaction to DCBdGTP. 
DCBdGTP were competing with dTT for the dNTP binding/polymerization site, its
inhibitory capacity would be expected to be inversely related to dTTP concentration. The
results of single point experients summarzed in Table TII-G, page 39, indicated such an
inverse relationship; only dTT, the substrate for this reaction, reversed DCBdGTP action
in this system.
(iv) DCBdGTP-induced inhibition in the presence of template cytosine apparently
involves a sequestration mechanism. To assess sequestration, I exploited the "scavenging
method employed to ascenain the induction of DNA:enzyme complex formation by H2-
HPUra (Gass et al. , 1973; Clements et al., 1975) and TMU (unpublished data). The
specifc experienta approach exploited poly(dA):oligo(dT)-drven incorporation of dTMP
and simply asked whether enzyme, in the presence of inhibitor at a concentration causing
minimal inhibition , can be sequestered by the addition of a small amount of a dC-containing
template:primer, an amount too small per se to interfere with dTT incorporation into the
oligo(dT). The results of relevant experiments comparng DCBG, DCBdGTP and a
TMU control are summarzed in Table llI- , page 40. All three inhibitors were used at
100 JlM; at this concentrtion DCBG, DCBdGTP and TMU, as expected from the results
shown in Table III-F, page 37, inhibited dTMP incorporation by, respectively, 2 40 and
5% (see top row Table TII-H, page 40). The addition of cytosine-containing activated calf
Conditions dN incorporation (a) (pmoles)
Control -DCBdGTP 11.9
Control + 100 IlM DCBdGTP
1 mM dATP + 100 J,M DCBdGTP
1 mM dCT + 100 IlM DCBdGTP
1 mM dTT(b) + 100 Il DCBdGTP 11.7
1 mM dGTP + 100 Il DCBdGTP
Table II-G: Effects of dNPs on DCBdGTP induced inhibition of pol III (a)
Incorporation of (3H) dTTP was monitored as described in Chapter VI, Section Fusing
poly(dA):oligo(dT) as template:prier and (3H) dTT at a concentration of 20 11M (825
cpm/pmole). (b) Under conditions of increased dTTP, the specific activity was lowered to
100 cpm/pmole.
(3H)dTMP Incorporation (pmole)
Template:Prer Control DCBG DCBdGTP TMU
(100 IlM) (100 IlM) (100 11M)
poly(dA):oligo(dT) 3.4 5.4
(2%) (a) (40%) (5%)
No homopolymer
(Activated cal thymus .:0. .:0. .:0. .:0.
DNA alone)
poly(dA):oligo(dT) +
Activated cal thymus DNA
(89%) (87%) (85%)
poly(dA):oligo(dT) +
Activated cal thymus DNA 3.4
+ dGTP (0.5 mM) (24%) (32%) (21 % )
Table III-H: Demonstration of sequestration. Poly(dA):oligo(dT) experiments were
performed with wild-type enzyme as descrbed in Chapter VI. Activated calf thymus DNA
was used at a concentrtion of 91lglml (1 :45 dilution of concentrations used in nonnal
assays). (a) ( %) = % inhibition; i.e. % of control.
thymus DNA at low concentration neither supported significant dTM incorporation (see
second row of data) nor drticaly reuced incorporation of dTM into poly(dA):oligo(dT)
(see thid row of data) in the absence of inhibitor; however, in its presence the effect was
dramatic. With DCBG or the control inhibitor, TMU, present, dTMP incorporation was
inhibited by approximately 90%, and in the presence of DCBdGTP, inhibition of dTMP
incorporation was increased from 40% to 87%. To determne if this drg-induced, DNA-
dependent inhibition was, as expected, sensitive to the presence of a high concentration of
dGTP (0.5mM), we examned its effect and, as a control , that of dATP and dCTP (not
shown). dGTP, when unaccompanied by inhibitor, exhibited a competitive action on
incorpration of dTM into poly(dA):oligo(dT) and decreased control values by 40%.
However, only dGTP was effective as a competitor; it reduced inhibition induced by
DCBG from 89 to 24%, that induced by DCBdGTP from 87 to 32% and that induced by
TMU from 85 to 21 % (see bottom row Table llI- , page 40). In sum , these results
strongly suggested that both DCBG and DCBdGTP, when provided with template cytosine
in an appropriate strctual context, act by a sequestration-specific mechanism typically
displayed by the pyrdine-based inhibitors such as TMU.
(v) DCBdGTP can serve as a substrate for its target enzyme. To investigate the
potential of DCBdGTP for polymerization , with the assistance of Dr. N aseema Khan, we
exploited sequencing gel analysis of prier extension , using the template:primer depicted in
the inset of Figure Ill- , pages 42-43. Experimentaly, I simply sought to determine if
DCBdGTP, like dGTP, could be utiized to extend the primer by one nucleotidyl residue.
The results are summarzed in the gel autoradiogram in the lower par of Figure III-
pages 42-43.
Prer (17mer) (Direction of synthesis)
. G T A A A A C G A eGG C C A G T
3' CAT T T T GeT Gee G GTe A CAT Gee GAT C C C S'
Template (29mer)
Figue II-E: Sequencing gel analysis of the substrate potential of DCBdGTP. Inset:
strctue of the template:primer. Lower panel: autoradiogram of the sequencing gel
electropherogram of the products resultig from pol TII action on the template:primer.
Details of the methods are descrbed in Chapter VI. Lanes: , template:primer (TIP)
control; B TIP + pol III; C, D, E TIP + pol III + DCBdGTP at 0.01, 1 and 10 11M
respectively; F, TIP + pol III + 25 11M dGTP; G, TIP + pol III + all 4 dNTPs at 25 11M
each.
There was, as expected, no primer extension in the absence of dNTP (lane B); only
paral degradation resultig from the activity of the enzyme s resident 3' 5' exonuclease
(Lw et al., 1976). The 17mer was extended to its full, 29mer length when all 4 dNTPs
were present (lane G), and, as expected, was extended by one residue when dGTP was
present as the sole dNTP substrte (lane F). The presence of DCBdGTP as the sole dNTP,
at concentrtions ragig from 0.1 to 100 ties its Ki (lanes C, D and E) resulted in the
formation of a product which migrted at the position expected for that of the primer
extended by one DCBdGMP residue. The Rr of primer extended by one DCBdGMP
residue is, under the conditions of electrophoresis I used, slightly, but consistently, lower
(-0.96) than that of the primer extended by one dGMP residue. The same is true when we
polymerze multiple molecules of DCBdGTP with termal deoxyrbonucleotidyl
trsferase to obtai a ladder of bands on the electropherogram (data not shown). Each
band rus slightly slower than that for the corresponding dGMP-terminated isomer
indicatig that molecules contanig DCBdGMP molecules are slightly larger and/or
bulker.
C. Conclusions
DCBdGTP behaved similarly to H2-HPUra in the in vitro experiments, described in the
previous section of this chapter, where it displayed a high degree of inhibitory potency on
bothwild ty and az-12 taget pol IIs. DCBdGTP-induced inhibition of activated DNA-
medated synthesis was specifcally reversed by dGTP, indicating that it, like H2-HPUra,
has a requirement for template cytosine. Unlike H2-HPUra, however, DCBdGTP
displayed nonspecific inhibition of poly(dA):oligo(dT)-mediated synthesis, indicating a
strong affinity for the dNTP binding region of pol Ill. DCBdGTP appeared to act via a
sequestration mechanism where it caused the formation of a reversible ternary complex
with pol il and the DNA template:prier. The above information suggested that the model
shown in Figure I- , page 13, for H2-HPUra-induced inhibition applies equally well for
DCBdGTP. Figure llI- , page 46, ilustrates the earlier sequestration model adapted with
the addition of a deoxyrbosyl trphosphate group to the simpler base inhibitor.
The evidence for polymerization of DCBdGTP by pol II suggests that DCBdGTP
formally occupies the dNTP binding site of pol III with a "fit" approximating that of the
dNTP it mimics, dGTP. This fit, when considered in the context of the characteristic, H2-
HPUra-like mechanism of DCBdGTP, which includes the abilty to promote ternary
complex formation, clearly perts the conclusion that the arl and dNTP binding sites are
formally distict and not overlapping. The alternative, that, at the time of polymerization
the arl group is displaced from its bindig site to make room for the incoming
deoxyrbosyl trphosphate group, is less likely to occur. The reasoning behind this
statement originates from the observed increase in Ki of the dNP inhibitor form over the
Ki for the base form, DCBG. This 5-fold increase (see Table Ill- , page 34) is likely due
to the addition of interactions of DCBdGTP with the amno acid side chains involved in
bindig the deoxyrbosyl rig and its 5' trphosphates to the interactions with the guanine
base and the N2_arl substituents. If the inhibitor arl domain were displaced during
binding and polymerization, I would expect the Ki for DCBdGTP to be in the range of the
Km for dGTP, at approximately 1- 11M. Instead, the observed Ki for DCBdGTP is 0.
11M. The additional observation that DCBdGTP had a five-fold greater potency on the
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Figure Ill-F: Proposed model ofthe DCBdGTP mechanism of action. Inhibitor sequesters
DNA and enzyme into a reversible ternar complex. Upon formation of the complex , the
phosphate is positioned for nucleophilc attack by the 3' OH group of the primer
termus. * indicates the base paied NH substituent which is a calculated distance of 6-7 A
from the arl binding domai of pol llI.
mutant az- 12 pol Ill, provides additional support to the hypothesis that the aryl domain
binds simultaeously with the binding of the deoxyrbosyl trphosphate moiety of
DCBdGTP.
The fit descrbed above and demonstrated in Figure llI- , page 46, suggests several
other importt conclusions regardig the strctue of the enzyme:inhibitor:DNA complex
and specifc features of the enzyme dNP bindig domai on which complex fonnation
depends. First, because DCBdGTP behaves similarly to H2-HPUra, which has been
shown, though NM experiments, to base pai with cytosine in a manner similar to
guanine, i.e. via Watson-Crck paig, one may infer that the geometr of the base pair
formed between the template cytosine and the N2-benzylguanine substituent closely
approximates that of the G:C pai formed in the process of dGTP polymerization. Second,
one may conclude that the N2-benzyl substituent does not formally occupy sites or space
crtical- to the cataysis of dN polymerzation; these include: (a) the amno acid side chain
substituents involved in the binding of the deoxyrbosyl ring and its 5' phosphates; (b) the
space about the 3' OH of the prier termus, and (c) the path between this OB group and
the ex phosphate of the incomig dNTP. Finaly, as a corollar to the above conclusions,
one also may envision more precisely the location of the major site of inhibitor:enzyme
interaction, the so-caled arl binding site (Brown et al., 1986). Specifically, the model
suggests that this site lies on the "edge" of the dN binding domain in space defined by a
radius of 6-7 Angstroms from the unpaired proton on the exocyclic 2-amino group of a
base-paied dGTP molecule, or the base paied 2-NH of DCBdGTP (the * in Figure III-
indicates the position), as they await polymerization.
CHAPTER IV
SEARCH FOR A POL III INHIBITOR FORM POTENTIALLY USEFUL
AS A COVALENT MARKER OF THE ARYL BINDING SITE
A. Approach
Dr. George Wright, in collaboration with Dr. Brown, has synthesized a considerable
numbe of inhibitors of Gram+ pol III substituted in the arl ring with groups capable of
formng a covalent bond with appropriately reactive amno acid side chais. Whereas the
potential of these forms as covalent markers had not been systematically analyzed, I
proposed such an analysis, and to faciltate the experiments, I proposed the design of an
enzyme specificaly mutated at serie 1175 (S 1175).
nale for ta eti g amino acid . The choice of S1175 was based on its
specific effect on the drg sensitivity profie of pol III azp 12, a mutant enzyme derived
from aB. subtils mutant selected for its abilty to grow on medium containing HPUra
(Clements et al., 1975). The point mutation of polC az-12 results in a change of serine
residue 1175 in the wild-type enzyme to alanine (S 1175A) (Bares et al., 1989; Sanjanwala
& Ganesan, 1989). Table IV-A, page 49, compares the sensitivity of the serine and alanine
enzymes toward H2-HPUra and 6-(phenylhydrazino)uracil (H2-PUra),
Ki (JlM)
Inhibitor Wild type Azp-Form (Ser 1175 - 0H) (Ala 1175 -ClI)
0.4
Hz-HPUra
1.4
Hz-PUra
Table IV -A: Effects of H2-HPUra and H2-PUra on inhibition of wild-typ vs azp-12 pol
Ills. KiS were determned as described in Chapter VI.
(arlhydrazino)uracils diferg only with respect to the presence/absence of the hydroxy
substituent in the para position of the arl rig.
As the results in Table IV - , page 49, indicate, the mutation has little effect on the
enzyme s ability to bind the un substituted ring ofH2-PUra, while it reduces nearly ftfty-
fold the affmity of the p-hydroxylated H2-HPUra against which it was selected. Although
there are many possible explanations for the differential reactivity to the hydroxyl form of
the inhibitor, I proposed the following hypthesis as the basis. I suggested that the
CH20H side chain of serine 1175 lies on the periphery of the arl binding site, positioned
such that it does not significantly influence the binding of the unsubstituted arl rig but
close enough to react with polar substituents (i.e. OH) which extend from the para and/or
the meta positions of the ring (I included meta-substituted 6-anilnouracil analogs in this
hypothesis because many such compounds are effective pol III inhibitors (Wright &
Gambino, 1984). In the wild-tye enzyme, the polar -CH20H serine side chain is
envisioned to form a hydrogen bond with the OH group, faciltating the binding of the
arl moiety. Conversely, in the mutat enzyme, the hydrophobic -CH3 side chain ofthe
alanine is envisioned to repel the polar OH group ofH2-HPUra, thus reducing the
strengt of binding of the arl moiety.
If the above hypothesis regardig the positioning of residue 1175 were correct, an 1175
side chain would, in theory, be avaiable for direct covalent attack by a suitably reactive
group placed in the para and/or meta position on the inhibitor s arl ring.
:;i
The collection of potentialy reactive phenyl-substituted inhibitor forms which I had
available to test my hypothesis fell into two classes: those with halomethyl substituents
-;?" '
(i.e. -CH2CI and -CH2Br) and those with a mercaptomethyl group (-CH2SH) (Table IV-
pages 51-52). Because both classes of inhibitors were liely to be more reactive for the
Table IV-
HNj
Target
N-X Reactivity Residues
.! CH (Br, Cn
x= 
CH2SH (cys)
Dirt
Dirt SH (cys)
Requies Cys, Ser, Tyr
photoactivation , Phe, Lys
to nitrene
Forms a
reducibleDirt Schiff base with
lysine NH2
5 1
Table IV-B: Potential covalent inhibitors of pol llI-cys. Inhibitors from categories 1 and 2
have been synthesized. The last two forms of inhibitor can readily be synthesized.
Synthesis of inhibitor 3 would involve treatment of N2-(p-acetamidobenzyl)guane
(synthesized by reacting 2-bromohypoxanthine with the appropriate benzyl ame) under
basic conditions to yield the p-amno compound and subsequent treatment with sodum
azide and nitrous acid to yield the azido compound. Synthesis of inhibitor 4 would involve
the oxidation of N2-(p-hydroxybenzyl)guanine (previously synthesized by reacting 2-
bromohypoxanthine with the appropriate benzylamne) to yield the formyl compound.
cysteine side chai than for the serine side chai, I sought to constrct the correspondig
mutant enzyme S 117 5C. As an alternate, I sought to constrct an additional mutat,
S 1175K, in order to have an enzyme form capable of reacting with a formyl-substituted
inhibitor (Table IV- , pages 51- , inhibitor 4). Inhibitor 3, the p-azido-substituted
compound, would be useful in labeling both cysteine and lysine mutant forms as well as
the wild ty enzyme form.
B. Results
n of ol llI-cys and pol Ill-
(i) Site-directed mutagenesis. The mutagenesis system, obtaied from Promega,
exploited oligonucleotide-diected mutagenesis on a phagemid vector
, p-
SELECT,
contaning a single-stranded Fl origin of replication. This system, shown in Figure IV -
page 54, relies on the use of a second mutagenic oligonucleotide to confer antibiotic
resistance on the mutated DNA strand and thus provides a means to select and increase the
yield of mutat clones. p-SELECT contas a functional tetracycline resistace gene for
selection puroses and an inactivated ampicilli resistance gene for reactivation durng
mutagenesis (shown in Figue IV- , page 55). A small Pol C fragment, EcoRV
(nucleotide 2941) to BclI (nucleotide 3965) was inserted into the Bam site of the multiple
cloning site of p-SELECT. Single-stranded DNA was prepared from the resulting vector
and isolated for the subsequent mutagenesis reactions. Site directed mutagenesis was
performed, as shown in Figure IV -A, page 54, by anealng both mutagenic and ampicillin
na 
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Figure VI-A: Mutagenesis system obtained from Promega. Reproduced from the Promega
manual.
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Figure VI-B: p-SELECT plasmid map. Reproduced from the Promega manual.
repai oligonucleotides to the single-stranded DNA , synthesizing the mutat strand with T4
DNA polymerase, and sealng the mutat strand with T4ligase. The design of the pol II-
cys/pol llI-Iys mutagenic oligonucleotides is ilustrated in Figue IV -C, page 57. The
resulting DNA was transformed into a mismatch repair-deficient E. coli strain and selected
on the basis of ampicilln resistance. The isolated mutat DNAs were identied on the
basis of restrction site polymorphisms engineered into the mutagenic oligonucleotides
(Figure IV -C, page 57). An existing SacI site was changed to a unique Mael site in each of
the two mutations. Sequencing of a 200 base pai region of the mutagenized polC gene
served to screen for any other mutations. The sequenced region was then subcloned,
through several steps (descrbed in Chapter VI), into an E. coli-based overexpression
plasmid
(ii) Overexpression and purifcation. The cysteine-1175 and lysine- 1175 forms of 
subtils polC were generated by overexpression from the respective mutant expression
plasmids, which contained the A. phage leftward promoter, pL, in an E. coli strain which
contains the A. repressor, cI. Repression of the pL promoter by cI in this system is
controlled simply by adding naldixic acid (Nal) to an exponentialy growing cultue.
Induction of ths system inhibits replicative DNA synthesis, which in turn signals an SOS
response in the host (Little & Mount, 1982). This response induces the activity of a
protease which cleaves the cL repressor, relieving pL repression and thus, permts
transcription of any genes underpL control (Shatzman & Rosenberg, 1987). Assay of a
crude extract of the lysine 1175 form of pol II unfortnately displayed a very low level
polymerase activity (00 1 % of wild-tye) and therefore, this enzyme was of no furter use.
However, the cys form, pol llI-cys- 1175, displayed excellent activity and therefore, was
Converted serie 1175 to cysteine: 2 bases changed; 3569 and 3570.
Deleted Sac! site (Q 3553-3558 by changing 3558.
Added MaeI site (Q 3556-3559 by changing 355(C) (C A)
TCTGAGCT AGTTCAGA TTT GTGG CTTGTCTCA CG-
3550 MaeI 3560 3570 3580
Figure VI-C: Mutagenic oligonucleotide utiized to generate the change of serie 1175 to
cysteine. Bases in parentheses are wild-type sequences that have been replaced by the
bases in bold type. The oligonucleotide used to generate a serine to lysine change was
identical to the one shown above except that the sequence at bases 3568-3570 was AA (to
code for lysine).
subsequently pured though several steps, including Cibacron Blue, Phenyl sepharose
and Mono-Q columns (see Chapter VI), to yield a peptide of the expected 162.4 kDa size at
a level of purity of approximately 98% (Figure IV- , pages 59-60).
Characteristics of pol II-cys. I characterized the mutant protein in two contexts: 
vitro and in vivo, in the natural B. subtilis host. The in vivo characterization included
transformation of the mutat form of polC into wild-type B. subtils and assessment of the
impact of its pol Ill-cys- 1175 product on the growth and inhibitor (HUra type) response
phenotype of the transformed host. The in vitro characterization included assessment of the
basic catalytic propertes of the purfied protein. The results of the in vivo and in vitro
assessments are summarzed below and tabulated in Table IV -C, pages 61-62.
In vivo assessment. The polC-cys was transformed into competent wild-type 
subtilis by exploiting the HPUra resistace it conferred upon the recipient host. In
addition to the HPUra-resistant phenotype (Table IV -C, pages 61-62) the mutant protein
conferred a marginal, although signifcant, temperature sensitivity to its host; 51 C was
required to demonstrate this phenotype. Growth at 45 C did not effect differentiation
between wild-type and pol Ill-cys.
In vitro assessment. Relative to wild-tye pol II , the mutant enzyme displayed a 60%
reduction of the specific activity of the pol activity and only a 37% reduction in the exo
activity. This resulted in a lower pol:exo ratio for pol llI-cys. In effect, the pol activity
was more significantly impaired than the exo activity. There were no signifcant
differences with respect to the mutant enzyme s Km for dNs and native and
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Figue IV-D: SDS polyacrylamde gel electropherogram of Mono-Q FPLC-puried pol llI-
cys stained with Coommassie Blue. Lanes: A: molecular weight makers; B: Mono-Q
column load volume; C-F: Mono-Q fractions 41-44. Only fractions 42 and 43 (Lanes D
and E) were considered of sufficient purty for enzyme assays.
Table IV-
System Characteristics pol Ill-cys- 1175 Dol III wild-typ
In vivo Growth at 45 C in B. subtils (a) Strong growth Strong growth
Growth at 51 C in B. subtils (a) No growth Strong growth
Growth on HPUra in B. subtils 
(a) Strong growth No growth
In vitro Pol Specifc Activity (b) (units/mg) 2300
Exo Speifc Activity (c) (units/mg) 33.4 53.4
Polymerase:Exonuclease ratio (d) 68. 112.
Substrate Km
dA TP (IlM) 10.
dCTP (IlM)
dGTP (11M)
Activated C.T. DNA (llgfmL)
Poly(dA):oligo(dT) (units/mL) (e) 0.4
Poly(dC):oligo(dG) (units/mL) (e)
Table IV-C: Characteristics of pol II-cys1175 vs pol III wild-tye.
(a) 
B. subtilis strai BD54 (Cozzarell et al., 1975) (HPUra-sensitive) was trsformed
by wild-tye (pWT3) or cys mutant (pWTC3) DNA and selected at 300C on c+50 meda
containing 40 M HPUra. HPUra-resistant colonies were picked onto c+50 plates at
C, 45 C or 30 C or picked onto C+50 plates containing 40 M HPUra and grown at
300C. All colonies picked onto C+50 plates grew at 30
(b) One unit of polymerase activity is the amount of enzyme that incorporates into
activated calf thymus DNA 1 nmole oflabeled dN into a cold TCA-insoluble form in 10
miutes, under the conditions describe in Chapter VI. Protein quantities were assessed as
describe (Bradford, 1972).
(c) One unit of exonuclease activity is the amount of enzyme that releases 1.4 g (3.5 x
1() cpm) of 3H-Iabeled dTM in 10 minutes, under the conditions describe in Chapter
VI.
(d) The pol:exo ratio is based on the ratio of polymerase activity (units/mg) by the
method defied above in (b) to exonuclease activity (units/mg) defined above in (c)
(e) Units are OD260 absorbing units defined in Chapter VI, section G.
homopolymeric template:primers (Table IV -C, pages 61-62). The most remarkable
diference from wild-type enzyme involved inhibitor sensitivity. The pol III-cys-1175
displayed ::200-fold resistace to H2-HPUra and 20-fold resistance to TMAU (Table IV-
page 64). Interestingly, pol Ill-cys- I175 was indistinguishable from wild-tye with
respect to its susceptibilty to DCBG. A screening of several other inhibitors, ilustrated in
Table IV- , page 64, yielded results that were consistent with those descrbe above.
Those inhibitors with polar substituents were much less potent on pol Ill-cys (30-45-fold)
and those with hydrophobic substituents were less potent on pol llI-cys (about lO-fold).
Agai, those inhibitors which resembled DCBG, with chloro group substituents, were
equaly potent on both enzymes.
The propertes outlied in Table IV-C and Table IV-D indicated that S1175C was a
tolerable mutation which did not significantly impair the abilty of the enzyme to bind
template:primer and dNs. Although H2-HPUra-resistant, the enzyme could be
completely inhibited by high concentrations of inhibitors of the H2-HPUra form. In sum
the latter propertes and the relative stabilty of pol il -cys-117 5 made the enzyme a suitable
candidate as a target for ireversible inhibitor analysis.
ssess t o e potenti l irrev rsibl inhibitor . The approach was based on the
assumptions that covalent bond formation between an inhibitor substituent and a potentially
reactive residue at or near the arl binding site (i.e. side chai 1175): (1) would
ireveribly inactivate the polymerase activity of the molecule of pol II in which bond
formation occurred; (2) would show time-dependent inactivation; (3) would be enhanced
Inibitor Ki (11M)
pol III -cvs pol III wild tYpe
H2-HPUra (a) 0.4
TMU (b) 0.4
DCBG (c)
OH benzvlamouracil (d) 270
OH benzylguane (d) 840
Etp-Me anno uracil (e)
Me anino uracil (b) 160
Me phenylhydrazio uracil (a)
3,4-diCI anilinouracil (b)
diCI benzvlaminouracil (c)
Table IV -D: Potencies of reversible inhibitors of pol III wild typ and pol llI-cys. Ki
determinations were made as descrbed in Chapter VI. (a) Synthesis was described by
Wright and Brown, 1977. (b) Synthesis was described by Wright and Brown, 1980. (c)
Synthesis was describe in Chapter VI of this thesis. (d) Synthesized by Dr. L. Dudycz.
(e) Synthesis was descrbed by Wright and Gambino, 1984.
;0.;
by, if not require, the presence of an excess of template:primer to promote ternar complex
formation; and (4) inactivation would be specifcaly preventable by dGTP at high
concentrations, but not reversible by dGTP once effected. If the bond, indeed, involved
the side chai of residue 1175, one might also expect the -CH2SH of the cysteine mutant
enzyme to be considerably more susceptible to attack by electrophiles or sulfhydrl grups
than the -CH20H of the wild-type form or the -CH3 of the azp- 12 (S 1175A) form.
All potentialy ireversible inhibitors were tested, under standard polymerase assay
conditions, for their abilty to inhibit both wild-type and pol Ill-cys enzymes. The resulting
KiS, shown in Table IV- , page 66, ranged from 0. 18 11M to 125 11M. Each of these
inhibitors was considered to be suffciently potent for use in the ireversibilty assays.
Assays for assessment of ireversible inhibition. The standard polymerase assay
(Section G, Chapter VI) was modified to obtan conditions suitable for covalent bond
formation between inhibitor and mutant enzyme. Figure IV- , pages 67-68, ilustrates the
experiental conditions. First, enzyme was incubated at 25 C in the presence of activated
T. DNA, the requied buffer and Mg , and the inhibitor (Tube A). At varous tie
points, samples were removed from the A tubes and added to B tubes which contaied all
four dNs (which specifcally included a large excess of dGTP). Upon mixing the
contents of tubes A and B, the standard polymerase assay was initiated (see Figure IV-
and Section G, Chapter VI). The DNA template:primer concentration was kept in large
excess over enzyme concentration durig the initial period of incubation with inhibitor.
The rationale for the excess was to saturate the enzyme with DNA and inhibitor and provide
maximal ternar complex formation and, thus, maximal opportunity for covalent
inactivation by the inhibitor.
r\-
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Phenylguanine (PG)Anilourcil (AU)
i (
Inhibitor
wild-type pol III -cys
1. m-CH2SH AU (a)
2. m-CH2CI AU (b)
3. m-CH2Cl, P-CH1 AU (b)
4. m-CH2Br AU (a)
5. m-CH2Cl PG (c) 125
Table E: Assessment of inhibitor potencies with wild-type and pol il-cys using the
trncated (-dGTP) assay described in Chapter VI, Section G. (a) Synthesis was described
in Chapter VI of this thesis. (b) Synthesis was described by Wright et al., 1980. (c)
Synthesis was described by Gambino et aI., 1992.
At 0, 1, 2 and 4 hours
remove a sample from A
and add to B
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Assess polymerase
activity as percent of
control (sample from A
containig no inhbitor)
Incubate: Add to:
(3H)-dTTP (10 jlM)
dA TP (25 jlM)
dCTP (25 jlM)
dGTP (750 jlM)
Incubate at 30 C for 10 mi.
Standard polymerase assay
Enzyme, DNA
Buffer, Mg
+/- Inhibitor
(g 25
Figue IV-E: Conditions for assay for ireversible inhibition. Incubation mitures (300
J.) of mix A contaned 30 mM Tris-HCI (pH 7.5), 10 mM Mg(OAch, 25% glycerol, 0.
mg/mL activated calf thymus DNA and 1.61lg/mL pol llI-cys (approximately 0.
units/mL). Incubations were performed at C, and at 0, 1 , and 4 hours, 20 
samples were removed and added to 5 JlL of B mi contaiing 5x dN stock (30 mM
Tris-HCI (pH 7.5), 10 mM Mg(OAch, 125 JlM dATP and dCT, 50 JlM (3H)-dTT,
(625 cpm/pmole), and 3750 Jl dGTP) and incubated at 300C for 10 minutes. Reactions
were quenched and prepared for scintilation counting as described in Chapter VI.
The determation of activity, after incubation with inhibitor, as a percent of control
activity, in the presence of a large excess of dGTP was used as an indication of ireversible
inactivation of the polymerase. Table IV - F, pages 70- , summarzes the results of these
assays describe above and in Figure IV - E, pages 67-68. The fIrst line of the table
indicates that control values (minus inibitor) did not decrease significantly durg the four
hour incubation. TMU (second lie) was employed as a negative control beause the
nature of its arl substituent makes it an unlikely candidate for covalent bond formation.
Surrisingly, activity in the presence ofTMU increased during the four hour incubation.
This effect was not examned carefully, but was likely due to an abilty of the inhibitor to
stabilze DNA:enzyme complex formation or to cause renatuation of a paraly denatured
mutat enzyme. Examation of the results obtaed with inhibitors 1-5 indicated a pattern
of increasing activity, durg the four hour incubation, similar to that seen with TMU, the
negative control. The above results indicate a failure to demonstrate ireversible
inactivation of pol Ill-cys with inhibitors 1-
C. Conclusions and Discussion
age is ol III no a d 1175. Given the evidence presented in Section A
pages 49- , I chose the side chain of residue 1175 as a likely candidate for an "anchor
For covalent tagging, I engineered a change of the moderately reactive serie residue at
position 1175 to the more chemically reactive lysine and cysteine residues.
Although the lys form was expressed in high yield as a 162 kDa soluble protein , it was
barely active in polymerization. The loss of activity could be due to any number of factors.
Table IV-
% Activitv
Conditions tie 2 hours 4 hours
Control (no drg) 100
+ TMU (25 102 174 167
+ 1, CH2SH 
121 138
(30 
2, CH2CI 
120 152
(40 1l)
3, CH2CI
, p-
Me 200 225
(20 1l)
CH2Br 
159 180
(30 
5, CH2CI 
103 141
(20 
J ,
Table IV -F: Results of the assessment of ireversible inhibition. Conditions for the assays
are describe in Figure IV-E, pages 67-68, and were performed in the presence of a large
excess of dGTP (750 f.M, 250x its Km value) to effect reversal of inhibition by
competitive, non-ireversible inhibitors. Percent activity was calculated by dividig activity
(cpm) obtained in the presence of inhibitor by the control (-inhibitor) values and
multiplying by 100.
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For example, it is possible that the size or charge of lysine at position 1175 interfered with
the catalytic function of the pol active site and its capacity to bind dNT substrates.
Alternately, the presence of lysine at position 1175 may have disturbe the folding of the
polymerase as it was being synthesized. Or, the positively charged side chai may have
disturbe both protein foldig and catalysis by changing the ionic nature of its
envionment.
The replacement of serie 1175 with cysteine proved to be more successful in that it
yielded an acceptably active (40% the activity of wild-type) polymerase. The cysteine, a
more conservative substitution, was liely better tolerated, because the -CH2SH side chain
is much smaler than the lysine -(CH2)4-NH2 side chain and much closer in size to the
CH20H of the native serie residue. The -SH of cysteine must not be in a position to
form a disulfide brdge with another cysteine thiol; otherwise, it would liely have more
profoundly pertrbed the cataytic activity of the polymerase. The loss of 60% of the wild
ty activity upon mutation of serie 1175 to cysteine may have been a result of an overa
impaient of the mutat polymerase to 40% of the wild type activity. Another possibilty
is that 60% of the enzyme molecules were denatured and the remaining 40% maitained
the same activity as that of the wild type pol m. Evidence to support this possibility was
displayed durng assays for ireversible inhibition and wil be discussed later. The pol:exo
ratio, a measurement used to assess pol and exo domain mutants, of pol III-cys was less
than that of the wild-type enzyme. This observation is consistent with other evidence
(Hammond et aI., 1991) that suggests that the two domais are closely associated in the 
subtils pol II, but not so close that the pol and exo activities were equally afected by the
mutation at position 1175. An overall denaturation of the mutat enzyme would, in theory,
adversely affect the exo domain as well.
The negative results describe in Section B of this chapter did not invaldate our theory
that the side chain of residue 1175 is exposed in the arl binding domain. Whle pol 111-
cys- 1175 was highly resistant to polar arl inhibitor substituents such as the hydroxyl of
H2-HPUra, it also showed intermediate resistance to nonpolar arl substituents such as the
trmethylene group ofTMU. Ths latter form of inhbitor resistance is likely attbutable
to steric effects. Even though cysteine is a conservative substitution for sere, the atomic
radius of sulfur is 0.4 A larger than that of oxygen (He & Quiocho, 1991) and the cysteine
side chain has bond lengths and angles significantly different from those of serie (Frey et
al., 1973). The serie C to 0 bond length is 1.42 A vs 1.82 A for the cysteine C to S
bond length. The serine O-H bond length is 1.00 A vs 1.34 A for the S-H bond length of
cysteine. The greater resistance of the mutat enzyme for the inhibitors with polar
substituents could also be due to the diminished hydrogen bonding ability of the thiol group
of cysteine (Solomons, 1980) compared to that of the hydroxyl group of serine. The
chloro-substituted inhibitors, such as DCBG, 6-(3,4-dichlorobenzylamino)urcil, and 6-
(3,4-dichloroanilno)uracil, were equally potent on both wild-typ pol II and pol Ill-cys
(see Table IV - , page 64) suggesting that the drg resistaces discussed above were not
due to some overal strctul change occurrng away from the arl binding site but actually
involved a change in a residue that diectly contacts the arl moieties of inibitors. The
abilty of the chloro-substituted guanine and uracils to equally inhibit wild-type and pol II-
cys was liely due either to favorable spacing of these inhibitors in the arl binding domain
or to an optimal chemical interaction between the -CH2SH side chain of cysteine and the
para and/or meta substituents of the inhibitors. The above conclusions are only
speculation, since a complex quantitative strctue activity relationship analysis has not
been performed.
. -.. .
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e tested inhi tors d ot ire bly inhibit pol ID-cys. Each of the five potential
ireversible inhibitors that I had available was substituted in the meta position with the
alylating or disulfde bond-formg moieties. It is possible that the geometr of these
inhibitors was not appropriate; for example, the reactive species of inhibitor and side chai
1175 may either be not close enough or were too close for successful covalent bond
formation. Had I had more tie, I would have attempted to synthesize the corresponding
para-substituted inhibitors to test the latter possibilty; a change in positioning on the arl
rig may have mae a signifcant diference in reactivity.
Another possible factor for failure of the al.ylating inhibitors with -CH2Cl or -CH2Br
substituents was pH. The thiolate (S-) form of cysteine is far more reactive than the thol
(SH) form (Lundblad & Noyes, 1984). Whereas the pKa of the cysteine functional group
is 8.5, I attempted to perform the relevant incubations at pH 8.4 in order to obtai a higher
proportion of ionized cysteine. However, pol llI-cys was only marginally active at pH 8.4
and not active at higher pH (data not shown). The presence of a thiolate form of cysteine
may, indeed, be a prerequisite for successful nucleophilc attack of a halomethyl-substituted
inhibitor. An interesting experient would have been to incubate the enzyme at pH 8.4 and
then adjust assay conditions to pH 7.5. An appreciable amount of activity may then have
been recovered.
The incubation conditions for irreversible inhibition assays were minus the reducing
agent, DTT. I omitted DTT beause I thought that it might prevent or reverse the formtion
of a disulfde bond between cysteine 1175 and inhibitor 1 (mercaptomethyl substituted) if it
were present durng the incubation stage. It is certainly possible that the inhibitor could
dierize by formg a disulfide bond between two identical inhibitor molecules. This
possibilty was supported by the fact that inhibition at zero time was 60-70 % and virally
, - .
nonexistent after the preincubation for two hours, suggesting that the inhibitors were
somehow being inactivated. I later attempted to improve conditions by varing the
concentration ofDTT (20 M, 40 M and 100 M) durng incubation to perhaps disrupt
disulfide bonds between inhibitor molecules and allow the desired disulfide bonds between
inhibitor and cysteine. This attempt proved unsuccessful (data not shown), yielding
identical results as those obtaed without DTT. The faiure of the above attempts to
optize the conditions for covalent reaction may effectively eliate a -CH2SH side chai
in B. subtils pol il as a potentialy useful taget for covalently reactive inhibitor forms.
An alternate explanation is that, if the alylatig/sulfhydrl substituents did not come
close enough to cysteine 1175, they, as well as TMU, may have been able to renature a
paraly denatued enzyme without being able to covalently inactivate pol II-cys. This
phenomenon would liely increase enzyme activity by approximately 60%, the amount of
activity lost by pol llI-cys relative to wild type pol lll. Results in Table IV-F, pages 70-71,
indicate that several inhibitors actualy succeeded in increasing enzyme activity to 160% of
the control activity.
Did the failure of the compounds to irreversibly inactivate pol il-cys activity present a
failure to form a covalent adduct at position 1175? An alternate explanation for my faiure
to effect ireversible inactivation of pol il-cys is that a covalent adduct may have formed at
residue 1175 but may not have inactivated the polymerase, as previously hypothesized. It
is possible that a covalently bound inhibitor adduct could swing out of the dN-binding
region and not obstrct polymerization of dNM molecules. The only way to determne if
the above phenomenon were actually occurg would be to synthesize the inhibitor in a
radiolabeled form, subject enzyme and inhibitor to the incubation conditions descrbe
earlier, and determne whether radiolabel is actualy bound to pol llI-cys. Ideas for futue
experiments toward the goals of this project wil be discussed in Chapter V.
fi.
CHAPTER V
FUTURE DIRECTIONS
A. Contrbutions to the Long Range Goals of the Brown Lab
The research presented in this thesis has contrbuted towards one of the long rage
objectives of the Brown lab, which is to locate and to characterize the molecular strctue of
the dN and arl inhibitor binding sites of the B. subtils DNA polymerase il pol
domain. The major aim of my research was to determne, within the latter context, whether
these two sites were separate and distinct, overlapping, or completely congrous. I
successfully determined that the dNP and arl binding sites are formally distinct, but
close, positioned such that the arl moiety of a bound inhibitor molecule is but a few A
distant from space occupied by the hydrogen-bonded 2-NH group of a dNTP (Le. dGTP)
molecule as it sits in its prepolymerization position in the DNA:dN complex.
Using the latter information and strctue activity relationships obtained with 
substituted phenylhydrazinouracils and the mutant, azp- 12 enzyme, I hypothesize that the
para region of the arl group of bound inhibitor and the side chain of serie 1175 interacted
diectly in the ternar enzyme:inhibitor:DNA complex. On the basis of this workig
hypthesis, I attempted to redesign enzyme residue 1175 to optimize its covalent reactivity
for a suitably tailored inhibitor. I generated both a lysyl and a cysteinyl mutat; of the two,
only the cysteine form, pol llI-cys, was active and useful for study. Attempts to
ireversibly inhibit pol II-cys with potential covalently reactive forms of the H2-HPUra-
like inhibitors did not succeed. However, only a small number of inhibitors, mostly in the
meta-substituted anilnouracils, were tested. Furter promising candidates for covalent
reaction could readily be synthesized.
B. Furter Attempts to Define the Aryl Binding Site
Other otentiall irreversible inhibitors. In the second half of Table IV- , pages 51-
52, I proposed the synthesis and testing of two potential ireversible inhibitor forms which
had not been synthesized: 6-(p-azidoanilino)uracil and the 6-(p-formylanilno)uracil. The
former compound has excellent potential to label a broad range of amno acid side chais
and thus, could be used to label both wild-tye pol III and pol Ill-cys- 1175. The azido
group requires photoactivation in order to generate the reactive moiety, a nitrene group
(Rush & Konigsberg, 1990). The reversible ternar complex of enzyme:DNA:inhibitor
would have to be formed in the dak to assure the specificity of the reaction upon exposure
to light.
The second compound, 6-(p-formylanilno)uracil , is an aldehyde derivative like
pyrdoxal phosphate and thus, should be able to form a reversible Schiff base with
proximal lysine residues (Mitra & Metzler, 1988). A reduction reaction of this intermediate
with sodum borohydrde (NaBll) would form a covalent bond that cannot readily be
reversed (Tagaya & Fukui, 1986; Basu et al., 1988).
Methods exist to synthesize 6-(p-azidoanilno)uracil, or the equivalent guanine analog,
with a trtium label , to permt the detection of covalently linked inibitor (see Section C of
this chapter). The p-formyl-substituted inhibitor would not require synthesis of a trtium-
labeled form. Reduction of the Schiff base intermediate with (3H) NaBH4 (Basu et aI.,
1988) would introduce a trtium label into the lysyl-formyl double bond (-N=CH-) to yield
a single bond with two trtium labels (- N3H -CH3H - ).
Random mutagenesis of pole. Another approach to the tentative identifcation of arl
bindig domain residues would be to perform random mutagenesis on small segments of
the polC gene. The generation of random mutations could be accomplished through the use
of both in vivo and in vitro techniques. For example, the taget DNA can be propagated 
E. coli mutD ((Echols et al., 1983), a dnaQ gene mutant which has a deficient editing
exonuclease), for several generations to yield mismatch mutations (Schaaper, 1988).
Alternatively, the target DNA can be propagated in a plasmid withn an alylation repai-
deficient strain such as E. coli. ada- (Demple, 1986) and durng propagation be subjected to
treatment with an allating agent such as methylnitrosoguanidine. The resulting
chemically modified DNA gives rise to frequent mismatches in the DNA and thus, the
generation of mutations.
Mutated DNA obtained with either of the above methods can be inserted by
transformation back into the homologous segment of polC of a suitable 
B. subtils host
(N.C. Brown, unpublished results) and transformants selected on the basis of resistance to
a wide varety of strcturay modfied inhibitors in the benzyl guanne, HPUra or
anlinouracil famly (see Figure I-F, page 16). The latter approach should yield a varety 
point mutations specifying several inhibitor response phenotypes. PCR-mediated
, I
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sequencing of these mutations would provide a simple means to identify the mutated amo
acids specifying the phenotype and thus, yield, indirectly, a more detaled concept of the
arl binding site and identify promising residues for site specific attack.
C. Parallel Attempt to Label the dN Bindig Site
NT analo s. A well established method to identify active site residues of dNT
binding proteins involves their covalent cross-linking by varous dNs and 
analogs. One analog, 8-azido-dATP, has been used to covalently label the dN binding
sites of E. coli pol I Klenow fragment (Rush & Konigsberg, 1990) and mammalan
termnal deoxynucleotidyl transferase (TdT) (Evans & Coleman, 1989b) upon
photoactivation of the azido group to a reactive nitrene. A related compound, 5-azido
dUTP, also has been used as a photoaffinity label for 
E. coli pol I (Evans & Haley, 1987).
The above compounds can be readily synthesized in a (y_32P)-labeled form (Glynn &
Chappell, 1964) to permt analysis of labeled amino acid residues (see page 81).
Alternatively, the nucleoside analog, 5'
-(p-
fluorosulfonyl)benzoyl-8-azido-adenosine, a
bifunctional affnity label (Dombrowski & Colman, 1989), is potentially useful as an agent
for covalent labeling experiments, perhaps as the 2' deoxy derivative. The latter
compound, which can be labeled at the 2-position with trtium, has been used to label
bovine liver glutamate dehydrogenase. It contains a photoactivatable azido group, capable
of reacting with many amino acid side chains, and an electrophilc fluorosulfonyl group that
can react with a wide varety of side chains, including those of lysine, tyrosine, serie,
cysteine and histidine.
, ,
Direct cross-linking of dNs. If the above approach with dN analog labeling does
not work with wild-typ or mutant B. subtils pol Ills, direct U. induced cross-linkg
of dNPs could be attempted. This is a well established technique that has been used to
cross- link mammalian TdT and ribonucleotide reductase and E. coli pol I Klenow fragment
with (a32P)-dTT (Pandey & Modak, 1988; Pandey et al., 1987; Erisson et aI., 1982)
and E. coli pol III holoenzyme with (a32P)-dATP (Biswas & Kornberg, 1984). The
conditions required for the cross-ling experients have been described previously
(Erisson et aI., 1982).
Identification of labeled amino acid residues. If any of the above compounds
successfully label the arl and/or the dN binding sites, we would plan to identify the
labeled amo acid(s). The next steps in processing appropriately labeled protein would
involve its enzymatic cleavage into fragments, HPLC-identifcation and purcation of the
labeled fragment(s) (Kierdaszuk & Erisson, 1988; Evans et aI., 1989a), and sequencing
of the purfied peptide to identify its position in the protein (Rush & Konigsberg, 1990).
The experiments describe in the previous two sections wil liely diectly identiy key
anchor residues in the dNT and/or inhibitor binding sites and thus, provide a more
accurte account of the location of the pol il active site and provide a concept that should
faciltate the ultimate thee-diensional analysis of the enzyme strcture by X-ray
difraction.
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CHAPTER VI
MATERIALS AND METHODS
A. Chemicals and Reagents
Radoactive materials were purchased from New England Nuclear. Nucleotides and
synthetic polynucleotides were obtained from P-L Laboratories. Calf thymus DNA was
from Worthington. All chemicals, solvents and reagents used in syntheses were of
analytical grade or better and were obtained from Sigma unless otherwse noted.
B. Chemical Analysis
Melting points were determned on a Mel-temp apparatus. Elemental analyses were
performed by the Microanalysis Laboratory, University of Massachusetts, Amherst.
Phosphorus analyses were performed as described by Peterson (1978). UV spectra were
obtaied with a Gilford Response UV -Vis Spectrophotometer. NM spectr were
obtaned at 200 MHz with a Broer ACP-200 instrent; chemical shifts are reported in
ppm(S) relative to internal tetramethylsilane (lH) or external 1 % phosphoric acid (31P).
Only characteristic chemical shifts (ppm) and coupling constants (Hz) are given. The
identity of the nucleosides as 9-13(2-deoxyrbofuranosyl) derivatives was based on the
simiarty of IH NM spectra of sugar rig protons to those of 2' deoxyguanosine (Wright
& Dudycz, 1984).
C. Chemical Syntheses
N2-C3.4 orobe yDg e ( A solution of 2-bromohypoxanthine (10 g,
46.5 mmol) and 3,4-dichlorobenzylamne (16.4 g, 93 mmol) in 2-methoxyethanol (240
mL) and water (60 mL) was heated at reflux for 18 h. The reaction was stopped by
addition of ice water (300 mL). The product was isolated by fItration and crystalized from
methanol to yield 12.0 g (83%) of DCBG, melting point (m. ) 282-285 C. IH 
(Me2S0-d6) 0 12.42 (IH, s, 9-H), 10.69 (lH, s, I-H), 7.65 (lH, s, 8-H), 7.32-
(3H, m, Ph), 6.82 (lH, t, 2-NH), 4.49 (2H, d, CH2). Found: C, 46.31; H, 3.09; N,
22.36. C12H9NSOCI2 requires C, 46.47; H, 2.93; N, 22.58.
Synthesis of DCBdG, the nucleoside form of DCBG, was a four-step modfication of
the procedure describe by Wright et al. (1987); the approach to the synthesis of the
nucleoside mono- and trphosphates was based on that described by Wright and Dudycz
(1984).
Step 1: 2- (3.4 lamin rin A solution of DCBG (7.53 g,
24.3 mmol) in phosphoryl chloride (74 mL) contaning N, dimethylanilne (9 mL) was
heated at reflux for 10 min. The reaction miture was poured slowly into ice water (140
mL). After 1 h the solution was brought to pH 4 with sodium acetate, and the solid was
collected by fitration. The solid was dissolved in 0.5 M NaOH (100 mL), and the solution
was decolorize with carbon and acidified with acetic acid. The product was reisolated by
fitration and crystalized from methanol to yield 6.65 g (84%) of product, m.p. 196-
1980C. Amax (EtOH) 249nm (e, 13700), Amax (pH2) 247nm (e, 16900), A.ax (PHI2)
230nm (e, 37100). IH NMR (Me2S0-d() 88. 12 (IH, s, 8-H) Found: C, 43.95; H, 2.62;
21.09. C12HgNSCI3 requires C, 43.86; H, 2.45; N, 21.31.
Ste,p 2: (3.4-Dichlorobenzylamino )-6-chloro- (2-deoxy- 3. di-v-toluyl-B- D-
ribofuranosyl)purine. A miture of the step 1 product (5.65 g, 17.2 mmol) and sodum
hydrde (60% suspension in mineral oil, 0.72 g, 18.1 mmol) in dr acetonitre (125 mL)
was stied at C for 30 min. 2-Deoxy- di- toluyl-a- ribofuranosyl chloride (6.
g, 17.2 mmol) was added in small portions over a period of 50 min. The mixture was
diuted with chloroform (100 mL) and stied at C overnight. The mixtue was fItered
through Celite. The fitrate was evaporated to drness, and the residue was
chromatographed on a silca gel column (15 x 3 cm). Elution with a gradent of toluene-
20% acetone in toluene (4 L) gave two major products; the first, the desired product, was
crystallized from methanol to give 7. 11 g (61 % ) of the 9B isomer as colorless crstas with
a m.p. of 83- C. Amax (EtOH) 239nm (e, 41100), Amax (pH2) 239nm (e, 41900), Amax
(pHI2) 241nm (e, 41900). Found: C, 57.90; H, 4. 13; N, 10.10. C33H2SNSOSCl3
requires C, 58.21; H, 4. 14; N, 10.28. A second form, presumably the isomer, was
isolated but was uncharacterized.
Ste,p 3: 2- (3.4- Dichlorobenzy lamino )-6-chloro-9-(2-deoxy- B- D-ribofuranosyl)purine.
A stired solution of 2- (3,4-dichlorobenzylamno)-6-chloro-9-(2-deoxy- di- toluyl-
r1;
ribofuranosyl)pure (6.8 g, 10 mmol) in methanol (400 mL) was treated at 25 C with a
solution of 1 N sodum methoxide in methanol (20 mL). After 1 h the solution was
neutralzed with acetic acid, evaporated to dress, and the residue was chromatographed
on a silca gel column (10 x 2 cm). Elution with 10% methanol in chloroform (1.2 L) gave
the product, which was crystallized from methanol yielding 4. 11 g (92%) with a m.p. of
148- 150 C. Amax (EtOH) 254nm (e, 15400), Amax (PH2) 254nm (e, 15700), Amax
(pHI2) 254nm (e, 15500). IH NM (Me2S0-d() 0 8.28 (1H, s, 8-H), 6.23 (1H, t, J
9 Hz, 1' H), all other resonances as expected. Found: C, 45.61; H, 3.62; N, 15.47.
C17H16NS03CI3 requires C, 45.91; H, 3.63; N, 15.75.
Ste.v 4: N2-C3.4-Dichlorobenzyl)- (2-deoxy- ribofuranosyl)guanine (DCBdG).
solution of the step 3 product (0.85 g, 1.9 mmol) in ethanol (50 mL) was treated with 2-
mercaptoethanol (0.6 mL, 8.5 mmol) and a solution of 1 N sodum methoxide in methanol
(6 mL) and heated at reflux for 26 h. The solution was diluted with water (80 mL),
adjusted to pH 6.5 with acetic acid, and evaporated to dress to yield a crude product.
Crstaization from ethanol and then ethyl acetate gave 0.6 g (73%) of DCBdG with a
p. of 212-214 C. Amax (H20) 255nm (e, 11200), Amax (pH2) 258nm (e, 11500),
Amax (pHI2) 261nm (e, 10300). IH NMR (Me2S0-d6) 011.19 (IH , s, I-H), 7.83 (IH,
s, 8-H), 7.32- 61 (3H, m, Phe), 7.46 (IH, t, 2-NH), 6. 13 (IH, t, J = 6.9 Hz, 1' H),
27 (lH, d, 3' OH), 4.87 (1H, t, 5' OH), 4.50 (2H, d, CH2), 4.33 (1H, m, 3' H), 3.
(lH, q, 4' H), 3.57 (lH, m, 5' H), 3.47 (lH, m, 5" H), 2.55 (lH, m, 2' H), 2. 18 (lH
, 2" H). Found: C, 46.02; H, 3.93; N, 15.54. C17H17Ns04CI2.H20 requires C,
45.96; H, 4.31; N, 15.76.
.,-
N2-(3.4 orobe deo anos e 5 te ()C Phosphoryl
chloride (0.061 mL, 0.66 mmol) was added to a cold solution of DCBdG (256 mg, 0.
mmol) in trethyl phosphate (3.72 mL). The mixtue was kept at 0- C for 4 h durg
which more phosphoryl chloride (0.061 mL, 0.66 mmol) was added. The mixture was
kept at -200 overnight, and poured onto ice (25 g) and neutralzed with 1 N NaOH. The
product was applied to a 24 x 3.5 cm DEAE-Sephadex column, and the colum was eluted
with a linear gradient of 0. 1.0 M trethylamoniumbicarbonate, pH 7.7 (tota volume =
8 L), at a flow rate of 4 mL/min with collection of 15 mL fractions. Fractions containing
the desired product were combined, evaporated to dress, and the residue was dissolved
in methanol (1.2 mL) and mied with 0.5 M sodum perchlorate solution (5 mL). The
resulting suspension was centrfuged in a conical glass tube at 500 rpm for 10 mi.
Supernatant was removed and acetone (6 mL) was added to the pellet, and the suspension
recentrfuged. The latter procedure was repeated twice and the resultat pellet was
dissolved in H20 (4 mL) and lyophilzed. Recovery of DCBdGMP after conversion to the
sodium salt was 181 mg (55%). Amax (H20) 256nm (E, 12100), Amax (pH2) 259nm (E
12000), Amax (pHI2) 261nm (E, 10100). 31p NM (D20) 82.62 (t). Found: P, 5.86.
C17HI6NS07CI2PNa requires P, 5.87.
N2 (3.4 uano e 5 trphos hate A solution
of DCBdGMP, as the trethylammonium salt (102 mg, 0. 14 mmol), in
hexamethylphosphoramde (0.78 mL), was treated with 1 , 1'-carbonyldiimidazole (CDI
112 mg, 0.7 mmol) at 25 C. A clear solution was obtaied after 15 min, and after 1 h
more CDI (41 mg, 0.25 mmol) was added. The reaction was quenched after 1.5 h by the
addition of methanol (0. 125 mL). TLC showed complete conversion of DCBdGMP to its
imdazolyl derivative. A solution of trbutylamonium pyrophosphate, prepared from
tetrasodum pyrophosphate (320 mg, 0.68 mmol) by applying the material to a Dowex
colum previously equilbrated with trbutylamne, in hexamethylphosphoramde (6 mL)
was added dropwise with stirng. After 8 h at 25 C, the reaction mixture was poured onto
ice (25 g) and brought to 100 mL with water. The solution was applied to a 24 x 3.5 cm
DEAE-Sephadex colum and eluted with a linear gradient of 0.2- 0 M trethylamonium
bicarbonate, pH 7.7, (total volume = 3.9 L), at a flow rate of 2.7 mL/min with collection of
13 mL fractions. Fractions contaning DCBdGTP, at 0. 9 M buffer, were combined
and evaporated. The product was convened to its sodium salt by the same procedure used
for DCBdGMP. The product was lyophilized to give 64mg (59%) of DCBdGTP. Amax
(H20) 256nm (e, 11100), Amax (pm) 259nm (e, 1100), Amax (pHI2) 261nm (e,
10300). 31p NMR (D20) 8 - 56 (IP, d, y-P), - 10.85 (IP, d, a-P), -21.66 (1P, t, , J
= 17.6 Hz). Found: P, 11.75. C17H16NS013CI2P3N requires P, 11.38.
Meth lbenzyl) guanine. A solution of 2-bromohypoxanthine (1.5 g, 6.98 mmol)
and 4-methylbenzylamine (1.7 g, 13.96 mmol) in 2-methoxyethanol (36 mL) and water (9
mL) was heated at reflux for 18 h. The product was precipitated by the addition of an equal
volume of cold water. The precipitate was isolated by fitration and crystallized from
methanol to yield 0.95 g (54%) of product with a m.p. of 170- 172 C. Found: C, 59.02;
, 5.48; N, 26. 14. C13H13NSOl. 1/2 H20 requires C, 59.08; H, 5.34; N, 26.50.
ethy min uraci A solution of 6-chlorouracil (1 g, 13.6 mmol) and 4-
methylbenzylamne (3.3 g, 27.2 mmol) in 2-methoxyethanol (40 mL) was heated at reflux
for 7 h. The solution was evaporated to one-half volume, and the product was precipitated
by the addition of an equal volume of cold water. The precipitate was isolated by fItration
and crystalized from 50% acetic acid to yield 1 g (60%) of product which had a m.p. of
327-3300C. IH NMR (Me2S0-d6) 0 7. 12- 15 (4H, m, Ph), 6.55 (IH, m, 6-NH), 4.
(1H , d, 5-H), 4.20 (2H, d, CH2), 2.28 (3H, m, CH3). Found: C, 62.01; H, 5.52; N,
17.95. C12H13N302 requires C, 62.33; H, 5.67; N, 18. 17.
(3.4-Dichlorobenzylamino)uracil (DCBAU), A solution of 6-chlorouracil (0.5 g, 3.4
mmol) and 3,4-dichlorobenzylamie (1.2 g, 6.8 mmol) in 2-methoxyethanol (15 mL) was
heated at reflux for 18 h. The solution was cooled and an equal volume of cold water was
added. The precipitate was isolated by fItration and crystallized from ethanol to yield 0.45
g (45%) of product with a m.p. of 316-317 C. IH NMR (Me2S0-d6) 0 10. 12 (IH, s, 1-
H), 10.12 (IH, s, 3-H), 7.30- 64 (3H, m, Ph), 6.56 (IH, t, 6-NH), 4.35 (IH, d, 5-H),
4.30 (2H, d, CH2). Found: C, 45.80; H, 2.90; N, 14.54. Cl1H9N302Cl2 requires C,
46. 18; H, 3. 17; N, 14.69.
(m-Bromomethylanilno)uracil (6-(m-CH?Br) AU). A solution of 6-(m-
hydroxymethylanilino) uracil (Wright & Brown, 1980), (100 mg, 0.43 mmol) in 3 mL
HBr (48% in H20) was stired at room temperature for 48 hours. The product began to
precipitate durg the reaction. The suspension was poured into 30 mL of cold water, and
the precipitate was isolated by fitration and crstalized from 50% acetic acid (HOAc) to
yield 103 mg (81 %) of product with a m.p. :; 350 C. IH NMR (Me2S0-d6) 0 10.49 (IH
s, 3-H), 10.18 (IH, s, I-H), 8.33 (IH, s, 6-NH), 7. 12- 39 (4H, m, Ph), 4.74 (IH, s,
H), 4.72 (2H, s, CH2). Found: C, 44.99; H, 3.74; N, 13.90. Cl1HlON302Br
requires C, 44.62; H, 3.40; N, 14. 19.
6-(m-Mercaptomethylanlino) uracil. This synthesis involved two reactions: (1) A
solution of 6-(m-CH2Br) AU (100 mg, 0.34 mmol) and potassium thiocyanate (44 mg,
0.45 mmol) in DMSO (2.5 mL) was stired at room temperature for one hour. The
solution was poured into 25 mL of cold water, chiled and filtered. Identification of the
intermedate product, 6-(m-thiocyanatomethylanilino)uracil, was made by comparng
mobilty on TLC with an authentic product (prepared in the same manner by D. Trantolo,
doctoral dissertation, Clark University, 1982). (2) A solution of the crude product of
reaction (1) (55 mg, 0.20 mmol) in 2 N NaOH (6.25 mL) was heated at reflux for two
hours. Glacial HOAc was added to the solution until the pH became neutral. The solution
was chilled, and the resultig precipitate was fItered and crystalized from 50% HOAc to
yield 23 mg (49%) of product with a m.p. of 288-290oC. IH NMR (Me2S0-d() 810.46
(IH, s, 3-H), 10. 12 (1H, s, I-H), 8.26 (1H, s, 6-NH), 7.04- 34 (4H, m, Ph), 4.
(1H, s, 5-H), 3.75 (2H, s, CH2).
D. Bacterial Growth and Transformation
E. coli strainsBMH7I-mutS (Kramer et aI., 1984), JMI09, (Hanahan, 1985), and
XLI Blue (Stratagene) were grown on LB broth (Sambrook et al., 1989) plates containing
appropriate antibiotics and were made competent by the rubidium chloride method
(Hanahan, 1985). E.coli AR120 was induced in maximal induction medum (Mott et al.,
1985) and was made competent by the above method.
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B. subtils wild-type (Nevile & Brown , 1972) and F2 (Gass et al., 1971) were grown
in c+50 minimal salts medum (Anagnostopoulos & Spizizen, 1961) and were made
competent by a method described previously (Stewar, 1969).
E. Assay of Nucleic Acid and Protein Synthesis in Intact B. subtils
Wild tyeB. subtils was grown to log phase at 37 C in c+50 medium. At a time
designated as zero, either (3H) adenine (7 x 105 cpm/pmole, 100 M; for DNA and RNA)
or (3H) L-leucine (1.4 x 105cpm/pmole, 105 cpm/mL; for protein) was added to the cells
along with either DCBG (75 M), HPUra (75 M) or DMSO, the inhibitor diluent (Neville
& Brown, 1972). Periodcaly, duplicate samples (1 mL each) were removed to determne
incorporation of radioactivity into RNA, DNA or protein as describe previously (Brown,
1970). The radioactivity that was both cold TCA-precipitable and alkali-stable was counted
as DNA incorporation. The alali-soluble, cold TCA-precipitable material was counted as
RNA incorpration and was calculated by subtracting counts that were TCA-precipitated
but not alal-treated (DNA + RNA) from counts that remained after alali treatment
(DNA). The hot TCA-insoluble radioactive material was counted as protein.
F. Analysis of Prmer Extension
The method, performed by Dr. Naseema Khan in the Brown lab, involved the
autoradiographic analysis of denaturng DNA sequencing gel electropherograms of
products resulting from the extension of a 5' (32P)- labeled 17 residue oligonucleotide
r -
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prier annealed to a 29 residue template. The strctue of the primer (M13 sequencing
prier #1211; Boehrger Manheim) and template (Opron) is shown in the inset of
Figure Ill- , pages 42-43. The preparation of the sequencing gel (12% polyacrlamde, 8
M urea), 5' labeling of the primer with polynucleotide kinase, primer:template anealng,
sample prepartion, and the conditions for gel development and autoradiography, based on
work by Townsend & Cheng (1987), are described elsewhere (Khan et al., 1991). 
assay for extension, 0.25 units of FPLC/MonoQ puried pol III (see Section L, Chapter
VI, Hamond & Brown, 1992) were incubated in 101l of standard assay buffer (Nevile
& Brown, 1972), (plus 2 mM adenosine 5' -monophosphate (AMP) to parially inhibit the
associated exonuclease), in the presence of (32P)-primer:template, in slight excess over
enzyme, and in the presence or absence of selected dNs including DCBdGTP. Mter 5
mi. at 300C, incubation mitures were quenched and analyzed as descrbed (Townsend &
Cheng, 1987).
Cal thymus termal deoxyrbonucleotidyl transferase (TdT; New England Nuclear)
was used to obtain a sequencing ladder for identifying the specific products of prier
extension with DCBdGMP residues (Khan et al., 1991); 0.25 units ofTdT were incubated
at 37 C with l g of (32P)-labeled primer in the presence of 10 M DCBdGTP in a volume
of 10 Il in the assay buffer conditions describe (Roychoudr & Wu, 1980). After 30
min. the incubation mixtures were quenched and subjected to analysis as describe above
for the products of pol Ill-catalyzed primer extension.
G. DNA Polymerase Assay
All assays measured the incorporation of the labeled dN moiety of a radioactive
dN into a cold trchloroacetic acid (TCA)-insoluble form using varous DNA template-
primers. Insoluble DNA was fitered onto GF/A disks (Watman) and dred. Filter-bound
radioactivity was determed by scintillation countig of each disk in 2 mL of Optifluor
(Packard). Standard assays were done. as described by Barnes and Brown (1979).
Mixtures (25 JlL each) contaned 30 mM Tris-HCI , pH 7.6, 10 mM magnesium acetate, 4
mM DTT (Curn Matheson Scientific), 20% glycerol, 0.4 mg/ml activated calf thymus
DNA, 25 JlM each of dATP, dCTP and dGTP, and 10 JlM (3H)-dTT (625 cpm/pmol).
Reactions were initiated by the addition of 0.05 units of enzyme and incubated at 30 C for
10 min. One unit of polymerase activity is the amount of enzyme that incorporates 1 nmol
of labeled dN into a cold TCA-insoluble form in 10 miutes. Reactions were quenched
and DNA rendered insoluble by the addition of an excess of cold 10% TCA containg 10
mM PPi, and a furter incubation on ice for approximately 10 minutes.
Apparent inhibitor constats (Ki) were determned in the appropriate polymerase assay
conditions by either conventional kinetic competition assay or by trncated, dGTP-
deficient assay; both methods have been described (Wright and Brown, 1976).
Poly(dA):oligo(dT) and poly(dC):oligo(dG) were prepared by incubating at 500C a miture
of 4 Optical Density (OD) units (260nm) of polymer and 0.625 OD units of oligomer in 10
mM Tris-CI, pH 7.6, for 10 min. and allowing the mixture to cool to 25 C over an
additional 10 mi. period; O. IJl of this mixture was used in a final assay volume of 25
JlL. The labeled trphosphate, (3H)-dTTP or (3H)-dGTP, (20 JlM, 875 cpm/pmole) was
the only nucleotide used in experiments involving these homopolymeric templates.
1;.
H. Exonuclease Assay
The 3H-DNA template was prepared by scaling up a standard DNA polymerase assay
(see Section G) to 5 mL, increasing the specific activity of dTT to 1250 cpm/pmole and
incubation time to 20 miutes. The labeled DNA was precipitated by adding 0.5 mL of 7.
M amonium acetate and 11 mL of ice cold ethanol and freezing at -200C for 2 hours.
After centrugation, the pelleted DNA was resuspended in TE buffer (10 mM Tris-HCI,
pH 7.5, 1 mM EDTA), desalted on a Sephadex G-25 column and fItered. The DNA
(specific activity, 2.6 x 1() cpm/Ilg) was dissolved in TE to generate a stock solution
containing 1.5 x 1() cPm/IlL. To generate single strded DNA, the above solution was
heated to l00C for 5 min. and quenched on ice.
The exonuclease assay, which was a modified version of the procedure descrbed by
Low et al. (1976), was performed by adding 5 ilL enzyme (0.05 units) to a 45 Il reaction
miture containing 30 mM Tris-HCI, pH 7. 5 mM MgC12, 3 mM DTT, 10% glycerol
and 2.71lg of single stranded 3H-DNA (approximately 7 x 1() TCA-precipitable cpm) and
incubating at 300C for 10 minutes. The reaction was termnated by adding 50 Il of 10
mg/mL bovine serum albumi (BSA), 10 mM PPi and 500 Il cold 10% TCNIOm PPi
The mixture was centrfuged for 15 minutes and 400 ilL of the resulting supernatant were
counted in 2 mL of Optifuor (Packard).
J. Site-Directed Mutagenesis
The mutagenesis system, obtaied from Promega, exploited oligonucleotide-diected
mutagenesis on a phagemid vector
, p-
SELECT, containing a single-stranded Fl origin 
replication. This system, shown in Figure IV- , page 54, and Figure IV-B, page 55, is
described in Chapter IV. Procedures involving manipulation and cloning of recombinant
DNA were generally those described by Sambrook et al. (1989). Pol C fragment EcoRV
(2941) to Bell (3965) was inserted into the BamH site of the multiple cloning site ofp-
SELECT. Single-stranded DNA was prepared from the resulting vector by infectig 
coli JMI09 with vector and the helper phage, R408, at a multiplicity of infection of 10 (10
phage molecules per bacterial cell). Single-stranded DNA was isolated according to the
Promega manual, precipitated, and resuspended in TE.
Annealng was performed by miing prepared single-stranded recombinant DNA, an
ampicilli repai oligonucleotide and the appropriate mutagenic oligonucleotide (Operon),
shown in Figure IV -C, page 57, in the presence of 20 mM Tris- HCI, pH 7.5, 10 mM
MgCl2 and 50 mM NaCl. This mixture was heated to 700C for 5 min. and slowly cooled
to room temperature. Subsequent synthesis and ligation of double-stranded mutant DNA
was cared out by incubating the above mixture with 0.5 mM dNs, 1 mM ATP, 2 mM
DTT, T4 DNA polymerase (10 units) and T4 DNA ligase at 37 C for 90 mi.
Mutagenized DNA was transformed into E. coli BMH71-18 Mut S (a mismatch repai
deficient strai). The cells were grown overnight and the double-stranded DNA was
prepared in a mini-prep procedure based on the alkaline lysis method (Birboim & Doly,
1979). The DNA was then transformed into E. coli JMI09 (a recA deficient strain) and 6
colonies were agai miniprepped. The mutagenic oligonucleotide was designed to include
silent mutations which specifed the loss of a SacI restrction site (GAGCTC) and the
introduction of a unique MaeI site (CTAG). This restrction polymorphism provided a
diagnostic tool with which to tentatively identify successful mutations for confmnatory
sequencing. The dideoxy sequencing method (Sanger et aI., 1977) was used according to
the Sequenase Version 2.0 protocol (USB) to confmn the presence of the cysteine codon in
the polC-specific fragment, Bglll (3416) to Sacl (3613). Sequencing priers, obtained
from Operon, were employed by annealing one to the 3' 5' strand upstream of the BglII
and the other to the 5' 3' DNA strand downstream of the SacI site by heating the DNA to
700C for 5 min. and slowly cooling to room temperatue (see Figure VI- , page 96).
K. The Engineering of the Mutant Fragment into the polC Expression Plasmid, pKC30
The goal was to substitute the mutant BglI-SacI fragment for the equivalent fragment of
an engineered version of wild- type polC which had previously been designed in the
laboratory for constrction of the pol III expression plasmid pRHpolCwt (Hammond &
Brown , 1992). The essential features of the engineered polC fragment (nt 1-4311) are
shown schematically in the strcture of the recombinant plasmid pWTC3 in Figue VI-
page 97.
The specific procedure, which was dictated by consideration of the restrction site
morphology, consisted of the following four steps. The E. coli host for cloning steps 1-
was XLI Blue. The host for step 4 was coli AR120, a phage A lysogen which provides
the pL repressor protein, cI in trans. The product of step 4, pKBC6, must be propagated
EcoRV
1717
\ \, ,
B glI
3416
SacI
3613 
Sequencing prier
Sequencing prier
SELECT
Figue VI-A: p-SELECT vector containig the polC EcoRV to Bcli fragment and the
mutated codon 1175. Sequencing primers flanked the 197 b.p. BglII to SacI fragment. *
indicates the site of mutation.
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Bamll Cla BglI Sad Sacll2944 3416 3613 3851 Bam4900
E. coli RBS 
TCGGAGGMATAATGBam Met Glu polC nt4311
pW17C3
Figure VI-B: Strcture of the pol III recombinant plasmid, pWTC3, which contains the
entie polC gene and the E. coli ribosomal binding site (RBS), for optimal expression of
the gene inserted directly following it. * indicates the site of mutation. The met-glu codons
A TG GAA represent the fIrst six bases of native polC. DNA from bases 4312 to the
Baml site at nucleotide (nt) 4900 include a tandem aray of 553 nt of contiguous, non-
codng DNA from theB. subtilis genome and 36 nt ofp-Bluescript DNA (this DNA does
not affect the transcrption ofpolC in the expression plasmid (Hammond et al., 1991)
in the presence of cI to prevent synthesis of B. subtils pol llI, which is toxic to E. coli
(Bares et al., 1989).
(1) Agarose gel separation and NACS column (Gibco BRL) purfication of the mutat
BglI-SacI fragment and inserton into a subcloned ClaI-Bam (nt 2944-4864) fragment
of polC to produce pCBC1.
(2) Digestion of pCBCl with ClaI and SacII to generate a 907 bp fragment carng the
mutation. This was separated by agarose gel electrophoresis and purified by NACS
column.
(3) Insertion of the above fragment into pWT3,shown in Figure IV-B, page 97, that
was digested with ClaI and Sacll to generate pWTIC3, the cysteine mutant * version of
pWTI3.
(4) Digestion of pWTC3 with Bam, purification of the liberated 5 kb polC-specifc
fragment, and insertion into the BamHI site ofpKC30 (Rosenberg et aI., 1983)
downstream from its phage A leftward promoter, pL, to generate the expression plasmid,
pKBC6.
L. Induction, Overexpression , Purfication and Characterization of
Recombinant Pol Ill-Cys
The contol of the A. promoter/repressor-controlled system employed in this
overexpression is describe in Chapter IV. Two 1 L flasks of maximal induction medum
(Mott et al., 1985) contaiing ampicillin (150 Ilgirn) were innoculated with 14 ml of
overnight growth of AR120/pKBC6 and shaken at 32 C until an optical density at 600 nm
of 1.0 was attained. At this time, nalidixic acid was added to a final concentration of 60
Jlglrn and the incubation was continued for five hours. The cells were harested by
centrfugation, washed with cold phosphate buffered saline (PBS) contaning 1 mM
phenylmethanesulfonyl fluoride (PMSF) and stored as frozen pellets at -700C.
Purfication of pol il-cys was performed as described for wild-type pol III by
Hamond et al. (1992). Essentially, cells were ruptured with a French pressure cell under
1000 psi of pressure and then centruged to remove cellular debris. The supernatat was
then subjected to a series of column purfication steps.
The ftrst step involved tandem treatment with Cibacron Blue Sepharose (3G-A-agarose
type 3000-CL, Sigma) and Phenyl Sepharose (CL-4B, Sigma). Cibacron Blue, a
column with affinity for dN-binding proteins, allowed loading of the crude material at
low salt and eluting pol il at 3 M NaCL The eluent, which was loaded directly onto a
phenyl sepharose column, with a hydrophobic column matrx, was not assayed for
enzymatic activity due to the inhibitory effect of the 3 M NaCL Upon elution of the phenyl
sepharose column with low salt plus taurodeoxycholate (1DC), the eluate yielded pol il in
;;:
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a small volume. Polymerase activity was determned to be that of B. subti/is pol II by the
presence of 90% inhibition of activity in the presence of the pol II-specifc inhibitor,
TMU.
The second step of purification involved removal of the TDC through use of a Sephadex
25 (Phanacia) gel f1tration colum. The polymerase activity eluted imediately
following the void volume and was contaied in a volume that was 1.5x the load volume.
Smaller molecules, such as TDC, were bound on the G-25 column. The thid step
involved a fmal purcation of pol III by a NaCI gradient elution on a MonoQ (Phanacia)
column attached to an FPLC (Phanacia). The resultant protein, in pooled peak fractions,
42 and 43 (see Figure IV - , pages 59-60), had a purity of greater than 98% and the
correct, 162 KDa molecular weight compared to standard molecular weight markers.
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ABSTRACT
6-(Hydroxyphenylhydraino)uracil (H HPUra) is a
selecive and potent inhibitor of the replication-specific
class II DNA polymerase (pol II) of Gr+ bacteria.
Although formally a pyrimidine, H HPUra derives its
inhibitory activity from its specific capacity to mimic
the purine nucleotide, dGTP. We describe the
successful conversion of the H HPUra inhibitor proto-
type to a bona fide purine, using N -(benzyl)guanine(BG) as the basis. Structure-activity relationships of
BGs carrying a variety of substituents on the aryl ring
identified N .(3,4-dichlorobenzyl)guanine (DCBG) as a
nucleus equivalent to H HPUra with respect to
potency and inhibitor mechanism. DCBdGTP, the
-deoxyribonucleoside 5' triphosphate form of DCBG,
was synthesized and characterized with respect to its
action on wild-type and mutant forms of B. subtilis DNA
poilU. DCBdGTP acted on poilU by the characteristic
inhibitor mechanism and formally occupied the dNTP
binding site with a fit which permitted its poly-
merization.
INTRODUCTION
(p-
Hydroxyphenylhydrazino)uracil (H HPUra; ref I).
6-(phenylhydrazinoJuracil (PUra; ref 2). 6-(bnzylamino)uracil
and 6-(3A-trimethyleneanilino)uracil (BAU. TMAU: ref3) are
members of a family of 6-substituted pyrimidines (cf., Fig. IA)
which share a unique biologic propeny: they are novel dGTP
analogs which selectively inhibit the replication-specific DNA
polymerase II (pol Il) of B. subtilis and other Gr+ bacteria
(4-6J, The mechanism of inhibitory action common to this
family of bases (5.6) is summarzed schematically in panels B-
D of Fig. I, As shown in panel B. the inhibitor molecule consists
of two essential domains: a base pairing domain equivalent to
that of guanine. and an aryl domain from which it derives
reactivity and selectivity for its enzyme target. Panel C displays
the structure of the H-bonded, H HPUra:cytosine base pair,
and panel D summares how the bas pairing and aryl domains
of the molecule cooperate to effect inhibition. The inhibitor acts
as a bridge between the template:primer and the polymera
seuestering the enzyme into a reversible tern complex. The
bas pairing domain fonns one bridgehead with an unappose
templat cytosin intely dita to the 3' -OH termus. while
the aryl substituent fonns the other though its reaction with the
polymerase in the vicinity of its dNTP binding site.
We seek to charcterize in B. sOOrilis DNA pol II the loction
and molecular strcture of its inbitor bindig site an the preise
relationship of the latter to the site of dNT binding and
polymerition. Our strtegy has required the reconfiguration of
the inhibitor prototype into a bona fide guaine (G) fonnat to
provide a structure useful for mutat enzme selection and
suitable for development of 2' -deoxyribonucleotidyl fonns. Our
first attempt to adopt the G fonnt involved the anino prototype
and resulted in the conversion of TMAU to the Nl-(aryl)G
derivative, TMPG (cf.. Fig. I E). TMPG displayed the
appropriate mechanism and requisite enzyme selectivity.
However. TMPG was considerably less potent than TMAU and
penetrated cells very porly, and therefore. it was not suitable
for further development, As an alterntive to the 
-(aryl)-
guaine structure. we exploited the Nl-(arlalkyl)guine fonnt
to produce a series of W-(bnzyl)guanine (BG) derivatives. As
indicated in the results presented below
. the N benzyl fonnat
proved to be a fruitfu basis for inhibitor development. yielding
the novel bas, N2-(3.4-ichlorobenzyl)guaine (DCBG), and a
derivative. 2' -deoxyribonucleoside 5' 
-triphosphate fonn.
DCBdGTP, which can be polymerize by its pol II taget.
MATERIALS AND METHODS
Chemicals, reaents and bacterial strain
Radioactive materials were purchas from New England
Nuclea, Nucleotides an synthetic polynucleotides were obtane
from po Laboratories. Calf thymus DNA was from
Worthington. All chemicals. solvents and reagents used in
II T I, whom corrspondence should be 
addressed
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syntheses were of analytical grade or better. 
B. subtilis stranNB841 (7), which was use as the source of pol m. was grown
on minima sats agar supplemented as desribe (8).
Chemica anyse
Melting points were determined on a Mel-temp apparatu.
Elementa anyses were performed by the Microanysis
Laboratory. University of Massachusett. Amherst. Phosphorus
analyses were performed as describe by Peterson (9). UV
spetra were obtaned with a Gilford Response UV -VisSpephotometer. NMR spe were obt at 200 MHz with
a Bruker AC-P200 instrument; chemica shift ar reponed in
ppm (6) relatve to internal tetraethylsilane (IH) or external
phosphoric acid (3IP). Only chacteristic chemica shift (ppm)
and coupling constats (Hz) ar given. The identity of the
nucleosides as 9-/J-(2-ieoxyribofuraosyl) derivatives was bas
on the similarity of IH NMR spetra of sugar ring protons to
those of dexyguaosine and others (10).
Synthes
-(3, Dichlorobenzyl)guanine (DCBG). Reaction ofbromohypoxathe and 3.4-chlorobenzlam as desribe
(10) gave. after crystalization from methanol
. DCBG. in 83%
:L).
H,-HPUr. -:-0""
:-0
-Q\-Q
PUn
BAI
TI'AU
,11...(1t !TIlO Tt......,( STJIO
yield. m.p. 282-285 C, IH NMR (Me;S0-6) 6 12.42 (lH. s.
H). 10.69 (lH . s. I-H). 7.65 (lH. s. 8-H), 7.32-7.56 (3H.
m. Ph). 6.82 (lH. t. 2-NH). 4.49 (2H. d. CH
). 
Anal. Found:
C. 46.31; H. 3.09; N. 22.36. C OC1 requires C. 46.47;
, 2.93; N , 22.58.
Synthesis of DCBdG. the nucleoide form of DCBG
. was 
upon the proedure desribe in reference II; the approach to
the synthesis of the nucleoside mono and triphosphates was bas
on that describe by Wright and Dudycz (10).
Step 1: (3,4-Dichlorobenz/ano)-6-hloropurine. Treatment
of DCBG with phosphoryl chloride and crystaliztion frm
methol yielded 84% of prouct. m.p. 196-198 C. IH NMR(Me:SO ) 6 8. 12 (lH. s, 8-H). A1. Found: C. 43.95; H,
62; N , 21.09. C CI3 reuires C. 43.86; H. 2.45; N21.1.
Step 2:2- (3, 4-Dichlorobenz/aino )-6-hloro-9- (2-deoxy-/J-
ribojUranosyl)purine. Treannent of the sodium sat of the step
I product with 2-ieoxy- 5-ii- toluyl-/J-D-ribofuranosyl
chloride in acetonitrle gave two major products which were
separte by silica gel chromatograhy. The major desire
prouct was deblocked by treent with sodium methoxide in
Aryl
domain
f: 
Base pairing
domain
Un.l:ilFnrt
.Jr
H: 
,/",
Guanine FmmatlU 
,'"
fW 
: :, ,
: I
Frg I. (A) Sirucmre of relevanl 6-subslimted uracils. (8) A typica 6-anlinourail showing relevanl bas-paring an arl domans. eC) Ba-paring of H, HPUraan templale cytosine. CD) Inhibitor-induced seueslration of enzyme and DNA inlo a reversible tern complex. (E) Conversion of Ihe 6-anilnourail fonnl tothe corrponding guaine fonnt (regions involved in bas-paring are brackeled).
methanol. The product was crystallized from methanol and
isolaled in 56% yield. m. p. 148-150 C. IH NMR (M
08. 28 (IH. s. 8-H), 6.23 (lH, t = 6.9 Hz. I' H), all other
resonances as expected. Anal. Found: C. 45.61; H. 3.62; N.
15.47. C requires C. 45.91.; H. 3.63; N. 15. 75.
Step 3: (3. 4-Dichlorobenl:yl)-9-(2-deoxy-(3- ribojuranosy/)- .
guanine (DCBdG). The step 2 product was converted to OCBdG
by treatment with 2-mercaptoethanol in a solution of sodium
methoxide in methanol at reflux for 26h. Crystalization from
ethanol and then ethyl acetate gave 73% of DCBdG with m.
212-2WC. IH NMR (Me ) 0 11.9 (lH. s. I-H). 7.
(lH. s. 8-H). 7.32-7.61 (3H, m . Ph). 7.46 (lH. t. 2-NH), 6.
(lH, t. J = 6.9 Hz. I' H). 5.27 (IH, d. 3'-OH). 4.87 (lH,
t. 5' OH). 4.50 (2H. d. CH ), 4.33 (lH . m . 3' H). 3.81 (lH
q. 4' H). 3.57 (lH , m, 5' H). 3047 (lH. m. 5"-H), 2.55 (lH,
m. 2' H). 2.18 (lH, m , 2" H). Anl. Found: C. 46.02; H. 3.93;
N. 15. 54. CI7HI7 . H 0 requires C, 45.96; H . 4.31; N
15. 76.
-(3 , Dich/orobenzyl)-2 ' deoxyguanosine phosphate
(DCBdGMP). A solution of DCBdG and phosphoryl chloride in
trimethyl phosphate was kept atO-3 C for4h during which more
phosphoryl chloride was added. After chrmaography on DEA-
Sephadex and elution with a linear gradient of 0.2-I.OM
triethylammonium bicarbonate. pH 7.
. the product was
converted to the sodium salt by dissolving in methanol and
treatment with 0.5M sodium perchlorate solution. After
centrifugation and extensive washing with acetone. the resulting
pellet was dissolved in water and lyophilized. Recovery of
DCBdGMP after conversion to the sodium salt was 55%.
p NMR (0 0) 0 2. 62 (s). Anal. Found: P, 5. 86.
C17 PNa requires P, 5.87.
fV- (3 , Dich/orobenzyl)-2 ' deoxyguanosine -triphosphate
(DCBdGTP). A solution of DCBdGMP as the triethylamonium
salt in hexamethylphosphoraide. after activation by I,
I' -carbonyldiimidaole. was treated with tributylamonium
pyrophosphate. Chromatography of the diluted solution on
OEAE-Sephadex and elution with a linea gradient of 0.2 -I.
triethylammonium bicarbonate. pH 7. 7 gave the product. which
was converted to its sodium salt by the same procedure used for
DCBdGMP. The product was lyophilized to give 59% of
DCBdGTP. J1p NMR (D 0) 0 - 56 (lP, d
. "(-
P) , -10.
(lP. d. a-P). -21.66 (lP, t, (3-P). Anal. Found: P, 11.5.
C17 Na4 requires P, 11.38.
Purifcation and asay of B. subtiis pol II
Purification of wild-type and mutat (azpI2) pol II was
performed as described previously (12); unless specified
otherwise. the ONA cellulose fraction V was used in all
experiments. The standard assay for DNA polymerase II was
performed in a final volume of 25mL as describe (7). Apparent
inhibitor constats (K ) for each inhibitor were determed in the
appropriate polymerase assay conditions either conventionally or
by the truncated. dGTP-deficient assay method described by
Wright and Brown (13). Poly(dA):oligo(dT) and
poly(dC):oligo(dG) were prepared by incubating at 50 C a
mixture of 4 OD units (260nm) of polymer and 0. 625 OD units
of oligomer in IOmM Tris-CI (pH 7.6) for IOmin and allowing
the mixture to cool to 25 C over an additional 10 min period;
IILL of this mixture was used in a final assay volume of
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025ml. The labeled triphosphate (201LM, 875 cpmlpmole) was
the only nucleotide used in experiments involving these
homopolymeric templates.
Asy of nucleic acid and protein synthesis in intact B. subti
At time zero, eHI adenine (7X (OS cpm/pmole. lmM: for
DNA and RNA) or (3HI L-Ieucine (lAx IOScpmipmole. IOS
cpmirn: for protein) and DCBG (75ILM). HPUra (75ILM) 
OMSO (inhibitor diluent) were added to log phase cultures of
B. subtilis growing at 37 C in minimal salts medium (14). and
periodically. duplicate samples (I rn each) were removed todeterm incorpration of radioactivity into alkai-soluble (RNA)
and alkai-stable (DNA) frctions of cold TCA-insoluble material
or into hot TCA-insoluble material (protein) as describe
elsewhere (14).
Analysis of prier extension
The method involved the autoraiographic anysis of denatUring
DNA sequencing gel electropherograms of products resulting
from the extension of a 5' (32PI labeled 17 residue
oligonucleotide primer anneaed to a 29 residue template. The
structUre of the primer (M13 seuencing primer # 1211;
Boehringer Mannheim) and template (Operon) is shown in the
inset of Figure 3. The preparation of the sequencing gel (12 %
polyacrylamide). 5' labeling of the primer with polynucleotidekina. primer:template anneaing, sample prepartion. and the
conditions for gel development and autoradiography, were
performed as describe in reference 15. To assay for extension
25 units of homogeneous pol II (Fr. Vlla. ref. 12) were
incubated in IOILL of stadad assay buffer (7) in the presence
of (32PI-primer:template in slight excess over enzyme. and in
the presence or absence of selected dNTPs. After 5 min at30
incubation mixtUres were quenched and analyzed (15).
RESULTS
Properties of DCBG, the model benzylguanine
Following leads develope with 6-benzylamnouracil derivatives
as pol II inhibitors (3), we synthesized severa analogous
benzylguanines substitUted in the 3, 4 and 5 positions of the
benzyl moiety. Of these only DCBG displayed inhibitory potency
similar to those of H HPUra and related compounds. The
properties of OCBG are summarized in the following three
subsections.
(i) Action of DCBG on the isolated polymerase is characteristic
of the H HPUra prototype. Our strategy for pol II inhibitor
development required that in its simplest bas form. the product:(a) be at least as potent as the corresponding uracils. which
typically display Kjs in the 5-2ILM range; (b) be specifically
competitive with dGTP like the corrsponding 6-(bnzylamino)
and 6-(arylhydraino) uracils; and (c) be dependent on the
presence of a cytosine-containing template. The results of three
sets of experients , which are not explicitly displayed in tabulate
form. indicated tht DCBG fulf1led all these requirements. First.
OCBG was a characteristically potent inhibitor of wild-
type (WI)
pol II. displaying a K of approximately 5ILM. Second. its
inhibition was speifically and competitively reversed by dGTP;
high concentrations of dA TP , dCTP. or dITP had no effect on
its inhibitory capacity. Third, when the action of DCBG on pol
II was assessed, using either poly(dA):oligo(dT) or
poly(dC):oligo(dG) as template:primer. it. like H HPUra
(16. 17), inhibited only the latter reaction.
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(ii) Action on intact cells: specifcity for replicative DNA
synthesis. DCBG, like HPUra. the oxidized azo form of
HPUra which is reductively activated in vivo penetrated
intact B. subtils and inhibited its growt on plates. In liquid
medium , microscopic exam showed that 75ILM DCBG arrested
cell division and effected a segmented morphology typical of
HPUra-treted cells which are speifically unable to synthesize
DNA (14). Figure 2 summarzes the effect of DCBG on
macromolecule synthesis in log-phase B. subtilis exploiting
anysis bas on incorpration oflabeled adenine into RNA and
DNA. and labeled leucine into protein. The results clealy
indicate tht DCBG, like HPUra (1. 14). inhibits only DNA
synthesis and displays no significant effect on the synthesis of
RNA and protein.
(iii) Utility of DCBG as an agent for selecting an identifing
bacterial clones carrying mutations affecting the drug binding
site of pol /II. Much of the value of the H HPUra inhibitor
prototype as a genetic and structura probe of the replication-
speific DNA pol II is derived from its ' magic bullet ' capacity
to clealy and speifically select. on drug-contaning nutrient
plates. bacterial clones which car mutationally altered. drug-
reistat form of pol II. B. subtilis azp-12, a mutat displaying
both an HPUra-resistat growt phenotype and an H HPUra-
resistat pol II (17) exemplifies this strong corrspondence of
in vitro enze 'phenoty' and the growt-respons phenotype
of its host. As shown in Table I. comparison of the action of
DCBG and H HPUra on the. wt and azp-12-speific systems
indicated that DCBG also can consistently discriminate between
wt and mutat forms of pol II. both in vivo and in vitro. Table
I compas the potency of HrHPUra and DCBG as inhibitors
of the wt and azp-12-speific enzymes and their potency as
inhbitors of growt of the repetive wt and mutat hos bactria.
The top row of data. displaying Kjs. indicated that the azp-12
enzyme . relative to wt enzyme. shows approximately 55-fold
resistance to H HPUra and. interestingly, 5-fold higher
sensitivity to DCBG. The second row of data display the same
trend in vivo; the growt of the azp- 12 mutant host. relative to
that of the wt host. is 8 times more resistat to HPUra and 8
times more sensitive to DCBG.
30000 30000
Properties of DCBdGTP action on its pol II target
Given the promising behavior of DCBG describe above. we
asked whether the bas would retain its HrHPUra-like action
once converted to the dNTP form. The properties we sought in
the dNTP form were: (a) a potency at leat equivalent to that
of the simple bas form. DCBG; (b) a mechasm consistent with
that of the base. and (c) a structurally ' complete ' inhibitor form
that wil formally occupy the pol II dN binding site in the
maner of the dNTP it mimics. The results of experiments
desribe in subsetions (i)-(iv) below summare the properties
-fu
(i) Potency and discriminaon ofwr an mUtant pol Ills. Table
IT sum the effec of the 2' -dxyribonucleoide ofDCBG
and its 5' -mono an 5' -trphosphate on the wt an az12 -speific
enzmes. The addtion of the deoxyriboyl moiety to DCBG and.
in turn, the monophosphorylation of the nucleoside. derea
the potency of the inhibitors for the wt polymera and.
interestingly, had litte effect on their affnity for the mutat
enzme. Addtion of the (3 -
-y 
phospha to prouce the ultite
dNTP anog, DCBdGTP. reverse the trend to reuction of
potency for the wt polymera. yielding a K five times lowerth tht of the simple bas. Simary, DCGTP was four ties
more potent as an inhibitor of the azp-12-speific enzme 
of the wt enzme.
(ii) The tempi are cytosine requirement for DCBdGTP-indced
inhibition is not absolute. Competition experiments. identica to
those performed with DCBG. indicated th the inhibitory acion
ofDCBdGTP, in the presence ofactivated natura (calf thymus)
DNA . was competitively and speificay antagoni by dGTP;
dA TP. dCT. and dTIP at high concentrons in identica asy
conditions had no effec on its potency. Given the lattr
observation. we exploite the homopolymeric template:primers,
poly(dA):oligo(dT) and poly(dC):oligo(dG) to determne whether
the action of the dN form . like th of the pant bas. DCBG.
absolutely required template cytosine to effec inhibition. The
reults of the homopolymer experients ar sum in Table
II. DCBG . like H HPUra (16. 17). displayed no significat
inhibition in the absence of template cytosine. In contrt
5000
20000 RNA 20000
10000 10000
a 10 20 30 40 50 60 70
4000
DNA
3000
2000
1000
10 20 30 40 50 60 70 o 10 20 30 40 50 60 70
Time (min)
Figure 2. RNA. protein and DNA synthesis in Ihe presence of DCBG or HPUra. Cultures of B. sub/ilis NB841 were grown and incorpration of (" HI adenine
into RNA an DNA and r Hlieucine into prolein was followed as describe in the method setion. Inibitor. or conuol diluent were adde at time zero: 
. comrol: . .
75pM DCBG:.. 75pM HPUra.
DCBdGTP. although considerably more potent in the poly(dC)-
driven reaction (ICso = 7/tM). displayed significant activity
(lC = 200/tM) in the poly(dA)-directed reaction. Given the
superior structUral potential of DCBdGTP-relative to that of
DCBG- For templale independent binding to the dNTP binding
site of pol m. we hypothesize that DCBdGTP,induced inhbition
of the poly(dA)-driven reaction occured ' simply by direct
competition for the dNTP binding site with dTTP. the substrate
being polymerized. The results of competition experiments
employing the (dA):(dD reaction and the four dNTPs were
consistent with this hypothesis: only dTTP was competitive with
DCBdGTP action in this system (results are not shown).
(iiO DCBdGTP-induced inhibition in the presence of template
cytosine apparenrly im'olves a sequestration mechaism. 
assess sequestration we exploited the . scavenging , method
employed to asenan the induction of DNA:enzyme complex
fonnation by H HPUra (16. 17). The speific experimenta
approach exploited poly(dA):oligo(dT)-driven incorpration of
dTMP and simply asked whether enzme. in the presence of
inhibitor at a concentrtion causing minimal inhibition. can be
sequestered by the addition of a sm;jl amount of a dC--ontaning
lemplate:primer-an amount too small per se to interfere with
dTTP incorpration into the oligo(dD. The results of relevant
experiments comparng DCBG and DCBdGTP are summaried
Table I. In l'itTO vs in \;\" effec of DCBG and H, HPUra
wild type system
HPUra DCBG
azI systm
HPUra . DCBG
Islated pol 
K; (I'M"
Bacterial growth
CFU!O CI'M)'.' "
OA:. 5:. 22::4 1:.
,j'
was determned as described in Materials and Method. 
,'', CFU is the
ooncnlration of inhbitor in mima salS agar plates reire to reuce !h platig
offciencv of B. subrilis to 50% of contrl \'alues. ,,, HPUra. th o.idized dm2
tonn. was use in the plating experiments. 
Table II. POlency of the bas and higher fonns of DCBG
Compound
K; (I'Mf
"1 pol II azp 12 pol Fonn
DCBG
DCBdG
DCBdGMP
DCBdGTP
Bas
. -deoxyribonucleoside
dNMP
dNTP
5:.0:.
O:.
1 :.
1:.
1 :.
: .
005
5: .005
was determned as desribe in Materials and ethods. using acti\"ated calf
thymus DNA as template:primer.
Table II. Template dopendence of inhibitor action
(p.M),a.DCBG DCBdGTP
(a- " PI dGTP + poly(dC):oligoCdG)'"
HI dITP + polyld-\):oligO!dTI'"
250
::100 200
'al 
f) is the concentrtion of inhibitor reuire to reuce prouct fonntionby 50% of control ,'alues. ,b, Wild type pol II. '" Polymer:oligomer asy
-.ondicions are descri in the method 5ecion.
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in Table IV. Both inhibitors were use at lOO/tM; at this
concentration DCBG and DCBdGTP. as expeted. inhibited
dTMP incorpration by. respetively, 0 and 40% (cf., top row
Table IV). The addition of cytosine--ontaning activated calf
thymus DNA at low concentration neither supported significant
dDAP incorpration (cf.. seond row of data) nor dratically
reduced incorpration of dTMP into poly(dA):oligo(dT) (cf..
third row, in the absence of inhibitor; however. in its presence
the effect was dramatic. With DCBG present. dTMP
incorpration was inhibited by approximately 90% , and in the
presence of DCBdGTP. inhibition of dTMP incorpration was
increas from 43 to approximately 87%. To detennne if this
drug-induced. DNA-dependent inhbition was, as expeled
sensitive to the presence of a high concentrtion of dGTP
(0.5mM). we exaned its effec and. as a contrl. tht of dATP
and dCT. Only dGTP was effective as a competitor; it reuced
inhbition induced by DCBG from 90 to 25% and that induced
by DCBdGTP from 87 to 30% (cf. bottom row Table IY. In
sum. these results strongly suggested tht both DCBG and
DCBdGTP, when provided with template cytosine in an
appropriate structUra context. act by a seuestrtion-speific
mehasm tyicay diplayed by the pydie-b inbitors.
(i\' DCBdGTP can serve as a substrate for its target enzyme.
Unlike the parent bas, DCBdGTP had the potential for
polymerition by pol m. To investigate th potenti. we
exploited sequencing gel anysis of prier extension, using the
template:prier depict in the in of Figu 3. Experintay,
we sought to detennne if DCBdGTP. like dGTP
, could be
utilized to extend the primer by one nucleotidyl reidue. The
results ar sumar in the gel autoraogr in the lower 
of Figure 3.
There was. as expeted. no primer extension in the absence
of dNTP (lane B)-only parial degration resulting from the
activitY of the enzvme s resident 3' 5' exonucleae (18) which
could be partially inhibited by the addition of 2 mM AMP (lane
C). The 17mer was extended to its full . 29mer lengt when al
4 d:-Ps were present (lane H). and, as expeted, was extended
by one residue when dGTP was present as the sole dNP
substrte (lane D). The prence ofDCBdGTP as the sole dNT.
at concentrations raging from 1 to 100 times its K (lanes E.
F and G) resulted in the fonnation of a product which migrated
at the position expeted for that of the primer extended by one
DCBdGMP residue (note: The Rr of primer extended by one
DCBdGMP residue is. in the conditions of electrophoresis,
Table IV. Demonstration of seuestration
Template:Prmer
HJdTMP Incorpraon (pmole)
Control DCBG(lOOI'M) DCBdGTP(lOOI'M)
poly'dA\:oligO!dTI'"
No homopolymer
Act\'ated calf th\'mus
D:-A'.' alone
poly'dA):oligO!dTI +
Acti\'ated calf thymus DNA
polyCdA):oligoidTI +
Activated calf thymus DNA
-r dGTP to. 5mM)
0:0. 0:0. 0:0.
'" Poly(dA):oligoidTI e.periments were perform with wild type enzme as
desribe in Materials an Method. ,., Activate caf thymus DNA was use
al a oonntrtion of 91'81 mI (I :45 diution of cotrtion us in norm asys).
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Prmer (17mer)
S'oGTAAAACGACGGCCAGT 
J' C A TTTT G CTG CCG GTC AC A TG CCG A TCCCS'
Templale (29mer)
FIgre J. Analysis of the subslrate potential of DCBdGTP. Inser: strcture of
remplare:prir. Lo....r pal: Autoraiogph of seencing gel elecro
of the proUCIS resulring from pol II action on the template:primer. The details
of the proure are describe in the methods section. Loes: A. I.
Primer:template (pm controls: B. prr + pol II: C. prr + pol II + 2mMAMP (to paniaJly inhibit J' 5' exonuclease): Lanes D-H contain AMP: D. prr
+ pol II + 25 pM dGTP: E. F. G: prr + pol II + DCBdGTP at 0. 1. 1.0
an 10 pM. respetively: H. prr + pol II + all 4 dNTPs at 25 pM each.
slightly. but consistently. smaller ( - 0.96) than that of the primer
extended by one dGMP residue). Although clearly functional as
a polymerizable substrate. DCBdGTP was less effective than
dGTP; compave densitometry of the N + I products of prier
extension by 25/1M dGTP (lane D) and IO/IM DCBdGTP (lane
G) indicated that in these conditions the rate of DCBdGMP
incorpration was approximately 5 - 10% that of dGMP.
DISCUSSION
The benzylguanine format provides structural versatility
without disruption of the characteritic inhibitor mechanism
The goa of this work was to expand the utility of the H HPUrainhibitor class as pol Il-specific genetic and structural probes.
Specifically. we sought to develop a rationally structured series
of inhibitor forms of increasing complexity. ranging from the
simple base. which can specifically access and sense wild-
typeand mutant forms of pol II in the intact host. to the
-deoxyribonucleosidyl and nucleOtidyl forms. whose structure
can be manipulated appropriately to probe the structure and
function of the dNTP and inhibitor binding site of isolated
enzyme.
The NZ-benzylguanine format. represented specifically byDCBG, provides an excellent basis for the inhibitor series we
seek. The propenies of the simplest. base form are essentially
identical to those of H HPUra. DCBG penetrates cellseffectively (cf.. Table n. and chemically it is clearly 
adaptable
to 9-(3-D-nucleosidation and nucleotidation without loss of its
essential H HPUra ' character
. including (he ability todistinguish wild-type and mutant forms of pol 
II (cf.. TablesI and II.
Significance of the polymeriztion of DCBdGTP
Although DCBdGTP is less effective as a pol II substrate than
dGTP. it. nevenheless , panicipates successfully in the catalysis
of polymerition (cf.
. Fig. 3). The polymerition of DCBdGTPindicates that it formally occupies the enzyme s dNTP binding
site with a ' fit' approximating that of the dNTP it mimics. This
fit, when considered in the context of the characteristic, base
(HPUralDCBG)-like behavior of DCBdGTP
. permits severalimponant conclusions regarding the structure of the
enzyme:inhibitor:DNA complex and specific features of the
enzyme s dNTP binding domain on which complex formation
depends.
First, one may firmy conclude that the geometry of the base
pair formed between the template cytosine and the
benzylguanine substituent closely approximates that of the
G:C pair formed in the proces of dGTP 
polymerition. Second
one may conclude that the N2 benzyl substituent does nOt
formally occupy sites or space critical to the cataysis of dNTP
polymerion; these include: (a) the substituents involved in the
binding of the deoxyribosyl ring and its 5' phosphates; (b) the
space about the 3' OH of the primer terminus. and (c) the path
between this OH group and the a phosphate of the
. incomingdNTP. Finaly. as a corollar to the above conclusions. one also
may envision more preisely the location of the major site of
inhibitor:enzyme interaction-the so-called 
arl binding site (6).Specifically. one may conclude that this site lies on the '
edge
of the dNTP binding domain in space immediately surrounding
the unpaired H constituent of the exocyclic 2-amino group of
an appropriately base-paired dGTP molecule.
Potential of DCBG derivatives as probe for in vito analysis
of the structure of pol il and its dNT binding site
The four major forms, DCBG. DCBdG. DCBdGMP, and
DCBdGTP
. provide a rich varety of options for fining theinhibitor with useful ' reponer' groups, in panicular groups
capable of forming covalent bonds with the inhibitor/dNTP
binding site. Among the positions most amenable to substitution
are the carbons of the N
-aryl ring. the 7 , 8. and 9 positions of
the base and. in the nucleoside and nucleotide forms, the 2'
and 5' carbns and the 5' -phosphoryl groups. Application of such
derivatives in combination with the manipulation and 
in vitro
expression of the pol II structura gene (19 - 21) should provide
a facile means to map and directly identity the side chains of
amino acids comprising the dNTP/inhibitor binding sites. Even
in the absence of covalently reactive substituents. DCBG
derivatives can be useful as probes of the dNTP binding site of
pol II. For example . DCBdGMP or non-polymerizable dNTP
forms thereof (i.e. Cl thio or (3.I'-methylene) have considerable
potential as reagents that can be exploited to promote the
crystaliztion. and in turn. the 3-D structural analysis of a pre-
polymerization DNA:enzyme:deoxyribonucleOtide complex.
The availabilitv of DCBG and structural variants increasthe utilty of the HPUra inhibitor clas as genetic in vivoprobe of pol III structure
rationally designed series of structural variants of a
mechanistically 'pure ' inhibitor class can serve as a powerfl set
of tools with which to probe the structure of inhibitor-specific
Nucleic Acids Research, Vol. 18. No. 24 7387
binding sites within a relevant taget protein. The utility of
multiple inhibitor form beomes even greter when their us
can be combined with manipulation of the cloned gene encoding
the target protein and the selection of gene mutats displaying
appropriate resistance/sensitivity phenotypes for the relevant
inhibitor variants. B. subtils WI and B. subtilis azp- 12 and their
respetive repons to HPUra an DeBG exemplify the poentia
of such a combined approh. B. subtilis azp-12 (serine to alanne
in codon 1175 of pol C; cf.. refs. 19-21) was obtained by
selection on HPUra; azp-12 confers upon pol II approximately
50-fold resistace to HPUra and. as shown in Table I. a: 8-fold
hypersensitivity to DeBG. The HPUrar/DCBG' phenotype of
bacteria caring azp-12 pennits counterselecion of an
appropriately mutagenize population of B. subtilis azp-12 on
DCBG (Butler and Brown. unpublished results). and. thus.
provides a very convenient meas to isolate and map both
intracodon- and extracQdon-specific pol mutations
acompaying the development of DCBG reistace. Replicaon
of similar approaches with appropriate combinations of pol 
mutants and the severa score of inhibitor varants now available
should provide a weath of deta abot the loction and molecular
structUre of both the inhibitor and dNTP binding domans of the
enzyme s active site.
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